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Cytotrophoblast extracellular vesicles promote 
maternal adaptation to pregnancy 
 
Sara Kristine Taylor 
Abstract  
Pregnancy requires integration between the embryo/fetus and the mother. The placenta 
promotes maternal adaptations to meet the physiologic, immunologic, and metabolic demands 
of the developing offspring. To mediate these changes, this temporary organ releases large 
quantities of extracellular vesicles (EVs) that facilitate communication between the embryo/fetus 
and the mother. Few studies have investigated the contents and functions of EVs from primary 
cytotrophoblasts (CTBs) at midgestation. In this study, I isolated EVs from second trimester 
CTBs by differential ultracentrifugation and characterized them by transmission electron 
microscopy, immunoblotting, and mass spectrometry. The 100,000 x g pellet was enriched for 
vesicles with a cup-like morphology typical of exosomes. They expressed the exosomal markers 
CD9 and hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) and the 
trophoblast proteins placental alkaline phosphatase (PLAP) and HLA-G. Global proteomic 
profiling by mass spectrometry showed that the placental EVs contained proteins with roles in 
localization, transport, and immune functions. A cytokine array revealed that the CTB 100,000 x 
g pellet contained a significant amount of TNF-a. In terms of uterine functions, CTB EVs 
increased decidual stromal cell (dESF) transcription and secretion of NF-kB targets, including 
IL-8, as measured by qRT-PCR and cytokine array. A soluble form of the TNF-a receptor 
inhibited the ability of CTB 100,000 x g EVs to increase dESF secretion of IL-8. Together, the 
data suggest that CTB EVs enhance decidual cell release of inflammatory cytokines, which may 
be an important component of successful pregnancy. In terms of extra-uterine sites, CTB 
 vii 
100,000 x g EVs promoted pancreatic b-cell proliferation and insulin production both in vivo and 
in vitro. Ultimately, this work identified CTB EVs as drivers of maternal adaptation to pregnancy 
at local and distant sites and creates a foundation to investigate functions of these vesicles in 
other tissues and in the context of pregnancy complications.  
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 2 
Overview 
 In the following chapters, I give the background for my thesis research in terms of 
placental biology and the relevant literature regarding extracellular vesicles (Chapter 1). Next, I 
describe the major findings of my research, which focused on placental extracellular vesicles 
(EVs). I characterized the size, morphology, and protein contents of two types of second 
trimester cytotrophoblast (CTB) EVs. I profiled their proteomes using mass-spectrometry 
(Chapter 2). By using a cytokine array, I identified TNF-a in the 100,000 x g EVs. Because CTB-
conditioned medium amplifies expression and secretion of NF-kB target, pro-angiogenic 
cytokines (Hess et al., 2007), I investigated the role of CTB 100,000 x g EVs and TNF-a in this 
process (Chapter 3). Also, we explored whether these vesicles play a role at a systemic level, 
specifically, in pancreatic adaptation to pregnancy (Chapter 4). Finally, I summarize the many 
future directions in which the findings presented here may advance the field (Chapter 5). 
 
The placenta orchestrates physiologic, immunologic, and structural integration of the 
maternal-fetal interface 
 Pregnancy presents unique physiologic and immunologic challenges to the mother and 
the embryo/fetus. The placenta mediates their physiologic integration. At a molecular level, this 
is accomplished by diverse molecules, including hormones and specialized placental proteins. 
At an immunologic level, the molecules and mechanisms are less clear, but likely include the 
numerous chemokines and cytokines produced at the maternal-fetal interface and the 
cytotrophoblast MHC class I molecule HLA-G (Ellis et al., 1986; Hemberger, 2013; Kovats et al., 
1990).  
 The placenta also mediates the physical integration of the embryo/fetus with the uterus 
and the maternal circulatory system. Its structure is diagramed in Figure 1.1. The component 
functional units are termed chorionic villi, which are classified as either floating or anchoring 
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(Robinson et al., 2017). Most of the placental surface is composed of floating villi, which are 
suspended in maternal blood (Maltepe and Fisher, 2015). Their surface is formed by 
syncytiotrophoblasts (STBs), multi-nucleated cells covered in microvilli, which increase the 
surface area and consequently diffusion, promoting nutrient and waste exchange (Smith et al., 
1977). Beneath the STB layer lie progenitor mononuclear cytotrophoblasts (CTBs), which fuse 
to form the syncytium (Robinson et al., 2017). The stromal core lies deep to the CTB layer and 
contains the villous vascular tree and connective tissue elements, including a specialized 
population of macrophages (Hofbauer cells)(Gaw et al., 2019; Red-Horse et al., 2005; Reyes et 
al., 2017). In anchoring villi, the CTB progenitors aggregate into columns, which leave the 
placenta and invade the decidua where they remodel spiral arteries redirecting blood flow to the 
floating villi (Red-Horse et al., 2005). The cohabitation of placental cells from the embryo/fetus 
and maternal immune, decidual, and muscle cells within the uterus requires fine tuning of 
tolerizing and inflammatory mechanisms (Hemberger, 2013).   
 We know that this process is critical to determining pregnancy outcomes. For example, 
shallow CTB invasion and reduced maternal spiral artery remodeling are associated with 
preeclampsia (Ball et al., 2006; Fisher, 2015).  
 
Extracellular vesicles 
 Extracellular vesicles (EVs) have emerged as a form of cell-cell communication. There 
are multiple types of EVs, including exosomes and microvesicles, which vary in size, cellular 
compartment of origin, contents, and function.  
 Exosomes range from 30-150 nm in size and originate in the endosomal compartment 
(Patel et al., 2019). They are formed by inward budding of endosomes into multivesicular 
bodies, which are transported to the cell surface where they fuse with the cell membrane and 
release exosomes into the extracellular space (Figure 1.2) (Harding et al., 1984; Pan et al., 
1985). When visualized by transmission electron microscopy (TEM), they typically exhibit a cup-
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like morphology, likely an artifact of dehydration in the TEM sample preparation process 
(Conde-Vancells et al., 2008; Raposo et al., 1996). Microvesicles are 100-1000 nm and are 
shed from the plasma membrane (Figure 1.2)(Raposo and Stoorvogel, 2013). The overlapping 
size of these two EV populations complicates the study of specific vesicle types. Thus, unless 
there are multiple purification steps, which may include immuno-affinity methods, samples will 
contain both exosomes and microvesicles. 
 EV cargo varies depending on what cells the vesicles are derived from and from where 
in the cell they originate. Overall, exosome contents reflect their origin in the endosomal 
compartment. They are enriched for tetraspanins, such as CD9, CD63, and CD81, and 
endosomal sorting components required for transport (ESCRT) pathway machinery, including 
tumor susceptibility gene 101 (Tsg101), Alix, and hepatocyte growth factor-regulated tyrosine 
kinase substrate (HRS)(Raposo and Stoorvogel, 2013). These molecules regulate the loading of 
other cargo into this subpopulation of EVs. For example, Tsg101 binds to the tetrapeptide motif 
P(S/T)AP to recruit other proteins, such as galectin-3 (Banfer et al., 2018). Additionally, the WW 
domain present in the Nedd4 family of ubiquitin ligases is sufficient for protein packaging into 
exosomes via binding to Ndfip1 and ubiquitination (Sterzenbach et al., 2017). There are likely 
other amino acid motifs that localize proteins to exosomes. These vesicles also contain a variety 
of RNA species. For example, exosomes are enriched with mRNAs that contain a 5’ terminal 
oligopyrimidine motif (Shurtleff et al., 2016). Contents also include small non-coding RNAs, 
including microRNAs (miRs) and transfer RNAs (tRNAs)(Shurtleff et al., 2017). Packaging 
mechanisms may vary by cell type depending on which RNA-binding proteins and RNAs are 
among the contents (Shurtleff et al., 2016). In terms of small RNAs, heterogeneous nuclear 
ribonucleoprotein A2B1 binds to the GGAG motif of miRs, which enables exosome loading 
(Villarroya-Beltri et al., 2013). Additionally, the Y-box binding protein I (YBX1) selectively sorts 
small noncoding RNAs, including miRs and tRNAs, into exosomes (Shurtleff et al., 2016; 
Shurtleff et al., 2017). In terms of other nucleic acids, exosomes contain double-stranded DNA 
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(Thakur et al., 2014) and mitochondrial DNA (Guescini et al., 2010; Sansone et al., 2017), but 
the mechanisms of packaging are unknown. 
Fewer studies have investigated the cargo of microvesicles, but the contents of these 
EVs appear to overlap that of exosomes (van Niel et al., 2018). They both contain proteins and 
nucleic acids. Microvesicles are enriched for protein contents that reflect their origin, such as 
plasma membrane structures, cargo that associates with lipid rafts, and cytoskeletal 
components (van Niel et al., 2018). In terms of nucleic acids, they carry mRNA, small non-
coding RNAs (including miRs), and DNA (Wei et al., 2017). Additional studies are needed to 
understand mechanisms of cargo loading into microvesicles.  
 
Exosome isolation methods 
Multiple methods have been used to isolate exosomes from in vitro-cultured conditioned 
medium and bodily fluids. Each has its advantages and disadvantages. Stepwise 
ultracentrifugation culminating at high speeds (between 100,000 and 110,000 x g) is the most 
commonly used method due to the low cost and relatively moderate amount of time required 
(Thery et al., 2006). However, the isolated pellet is not a pure population because the sizes of 
exosomes and microvesicles overlap. This exosome-enriched pellet also contains other 
contaminants, such as protein aggregates, lipoparticles, and apoptotic products (Hessvik and 
Llorente, 2018). 
Due to the limitations of ultracentrifugation, other techniques to isolate exosomes have 
been developed. Size exclusion chromatography is a rapid method that does not perturb the 
morphology of the resulting EVs, but the vesicles outside the chosen cutoff ranges will be lost 
and some level of cross-contamination due to size overlap is inevitable (Coumans et al., 2017; 
Gamez-Valero et al., 2016). Ultrafiltration uses a filter with either pressure or ultracentrifugation 
to separate EVs from soluble proteins. This rapid method produces higher yields than 
ultracentrifugation, but the preparation is contaminated by larger EVs and the applied force can 
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cause aggregation (Coumans et al., 2017). Polymer precipitation kits are a quick isolation 
technique with high recovery, but result in contamination by microvesicles, lipoparticles, and 
protein aggregates unless followed by additional purification steps (Duong et al., 2019; Hessvik 
and Llorente, 2018). Additionally, EVs generated by this method reduce viability of target cells in 
vitro, possible evidence of reagent spillover (Gamez-Valero et al., 2016). Therefore, 
downstream analyses should be considered when choosing an isolation method.   
Exosome preparations can be further purified after the initial isolation step by density-
gradient centrifugation and/or immunological isolation. For the former, the concentrated EVs are 
layered above or below a density gradient and ultracentrifuged, allowing for collection of 
exosomes at a density of 1.15 to 1.19 g/ml; however, this method is takes time and reduces 
yield (Hessvik and Llorente, 2018; Thery et al., 2006). Additionally, if the sample is concentrated 
by ultracentrifugation before this step, aggregation and physical disruption of vesicles may result 
in lower recovery (Duong et al., 2019). One study comparing exosome isolation methods 
followed by a density gradient step found that: (1) ultracentrifugation results in the lowest yields 
but highest purity; (2) polymer precipitation with a cushioned density gradient perform similarly; 
and (3) ultrafiltration produces the lowest purity preparations (Duong et al., 2019). 
Immunological isolation with an exosomal marker is another frequently used purification 
method, but it is time consuming and heterogenous expression of target antigens among 
exosome subpopulations may result in a significant loss of EVs (Ji et al., 2019; Shah et al., 
2018). Overall, the tradeoff between yield and purity poses a barrier to studying exosomes if the 
starting material is limiting.  
 
Extracellular vesicles as a method of cell-cell communication 
EVs are an emerging form of intercellular transport and communication. Signals to the 
recipient cell can take many forms. Multiple groups have used the Cre-loxP system to 
demonstrate exosomal cargo transfer to recipient cells in mouse model systems. EVs carrying 
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plasmid DNA, mRNA, and tagged protein for Cre-recombinase are taken up by their target cells, 
resulting in recombination (Kanada et al., 2015; Sterzenbach et al., 2017; Zomer et al., 2015). 
Another study took advantage of species-specific differences and found that exosomal miRNAs 
and mRNAs can be delivered to recipients, with subsequent translation of the latter (Valadi et 
al., 2007).  
Proteins on the surface of EVs are critical for uptake by recipient cells. The EV protein 
repertoire includes integrins and extracellular matrix proteins, which are required for homing to 
and uptake by target cells (Costa-Silva et al., 2015; Hoshino et al., 2015). Vesicular integrin 
expression does not always mirror that of parent cells (Hoshino et al., 2015). Small EVs isolated 
by ultracentrifugation at 100,000 x g have a variety of glycan modifications, including N-
acetylglucosamine and sialic acid residues (Williams et al., 2019). Perturbation of glycosylation 
changes uptake by recipient cells (Williams et al., 2019). More studies are needed to 
understand mechanisms by which EVs home to their targets.   
 EV functions have been described for many diseases and contexts, including cancer, 
immunity, and reproduction, specifically placentation. In the following sections, vesicles isolated 
by ultracentrifugation and an additional purification method, such as density gradient 
centrifugation or immuno-isolation, will be referred to as exosomes. EVs isolated by 
ultracentrifugation alone will be identified by the speed used to pellet them.  
 
Extracellular vesicle functions in cancer 
 EV function has been extensively studied in the context of cancer. They are present at 
higher concentrations in the blood of patients as compared to that of healthy control individuals 
(Capello et al., 2019). On a practical level, immortalized cancer cell lines facilitate production of 
the large quantities of conditioned medium required to isolate and purify exosomes from other 
EVs and contaminating material. Vesicles can function locally or at distant sites, facilitating 
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interactions of cancer cells with a variety of other cell types, including in the niche and at 
metastatic sites. 
 
EVs as a signaling mechanism between cancer cells 
 Multiple groups have reported that tumors use EVs to promote more aggressive 
behavior of subsets of their component cells. For example, malignant cells release EVs that 
carry mRNAs associated with migration and metastasis; these vesicles enhance these 
aggressive behaviors in less malignant recipient tumor cells (Zomer et al., 2015). Additionally, 
apoptotic glioblastoma cells promote proliferation and therapy resistance in the surviving cancer 
cells by transferring EVs containing oncogenic splicing factors (Pavlyukov et al., 2018). 
Furthermore, migrating HT1080 fibrosarcoma cells leave behind an exosome trail that promotes 
paracrine motility (Sung et al., 2015). Fibronectin on the surface of these vesicles enhances 
speed but not direction of movement (Sung et al., 2015; Sung and Weaver, 2017). Together, 
these studies demonstrate that EVs promote different aspects of tumor progression within 
cancer cell populations. 
 
EVs from the stroma as mediators of cancer progression 
 The stroma also releases vesicles that modulate cancer cell metabolism, therapy 
resistance, and disease progression. For example, bone marrow mesenchymal stem cells 
release 100,000 x g EVs that induce a dormant phenotype in metastatic breast cancer cells, 
reducing their proliferation and ultimately rendering them resistant to chemotherapy (Ono et al., 
2014). This is likely due to miR-23b present in the vesicles, as overexpression of this miRNA 
similarly decreases proliferation (Ono et al., 2014). Conversely, horizontal transfer of 
mitochondrial DNA in cancer-associated fibroblast EVs to dormant human breast cancer stem-
like cells restores metabolic activity and hormone therapy resistance (Sansone et al., 2017). 
Stromal cells also release EVs in response to tumor cell signals. When breast cancer cells 
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trigger NOTCH-MYC in fibroblasts, the stromal cells release unshielded RNA via exosomes 
(Nabet et al., 2017). Breast cancer cells take up these vesicles, which activate the pattern 
recognition receptor RIG-I, resulting in STAT1 antiviral and NOTCH3 signaling that drives the 
growth of therapy resistant cells and metastasis (Boelens et al., 2014; Nabet et al., 2017). Thus, 
EVs act as a form of intercellular communication between the stroma and cancer cells. 
 
EVs as a mechanism to modulate the primary and metastatic tumor microenvironments  
 Cancer EVs promote a favorable microenvironment at primary and pre-metastatic sites. 
These vesicles act in a paracrine manner at the primary tumor niche. For example, mouse 
GL261 glioma cells transfer miR-21 to microglia via 100,000 x g EVs in vivo, which down-
regulates miR-21 targets, including Btg2; downregulation of this gene increases microglia 
proliferation and supports tumor progression (Abels et al., 2019). Cancer EVs can also promote 
angiogenesis directly or through stromal cells. Hypoxic colorectal cancer cells release 
exosomes to promote the proliferation and migration of endothelial cells via Wnt/β-catenin 
signaling (Huang and Feng, 2017). Cancer cell exosomes trigger differentiation of fibroblasts to 
myofibroblasts via TGF-b1 (Webber et al., 2010). These exosome-induced myofibroblasts 
promote angiogenesis of human umbilical vein endothelial cells (HUVECs) in vitro and enhance 
tumor growth in vivo; TGF-b1 inhibition or blocking exosome production via Rab27a knockdown 
abolishes these effects (Webber et al., 2015). Soluble TGF-b1 does not recapitulate these pro-
angiogenic or tumor-promoting features, suggesting that the exosomal form of this growth factor 
has distinct functions and/or that these EVs contain other molecules that modulate the effects of 
TGF-b1 (Webber et al., 2010; Webber et al., 2015). Overall, these studies demonstrate multiple 
functions of tumor EVs in modulating nearby cells to promote tumor progression. 
 Cancer cells also release EVs into the circulation, where they establish the pre-
metastatic niche at distant sites in multiple cancer types. Metastatic melanoma exosomes 
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educate bone marrow-derived cells (BMDCs) through MET signaling and induce vascular 
leakiness and BMDC recruitment at the pre-metastatic niche, thus promoting metastasis 
(Peinado et al., 2012). Pancreatic ductal adenocarcinoma (PDAC) 100,000 x g EVs induce 
formation of a pre-metastatic niche and increase liver metastatic burden in mice (Costa-Silva et 
al., 2015). These EVs are taken up by Kupffer cells, increasing their secretion of TGF-b and 
upregulating hepatic stellate cell production of fibronectin, a pro-adhesion factor (Costa-Silva et 
al., 2015). This fibrotic environment increases recruitment of bone marrow-derived 
macrophages to the liver, which promotes metastasis (Costa-Silva et al., 2015). The adhesion 
and extracellular matrix (ECM) molecules on EVs determine exosome homing sites and where 
the pre-metastatic niche will form (Hoshino et al., 2015). Specifically, EV integrins ⍺6b4 and ⍺6b1 
promote lung metastasis, while integrin ⍺Vb5 promotes liver metastasis. Inhibition of integrins 
decreases EV organotropism, but overexpression increases EV uptake. Additionally, 
pretreatment with lung-tropic tumor EVs redirects metastasis of bone-tropic tumor cells to the 
lung (Hoshino et al., 2015). Thus, cancer EVs can function at distant sites to promote the 
formation of the pre-metastatic niche and disease progression.  
 
EVs as a mechanism of immune escape 
 Cancer cells release EVs to modulate the immune system and evade destruction. Tumor 
vesicles suppress differentiation, interfere with receptor binding, and contain 
immunosuppressive cargo. Uptake of cancer cell EVs interferes with normal differentiation of 
immune cells. For example, breast cancer exosomes suppress monocyte differentiation into 
antigen-presenting cells (Yu et al., 2007). Similarly, tumor cell 110,000 x g EVs prevent 
monocyte differentiation into dendritic cells, instead promoting the development of myeloid cells 
that suppress T cell function (Valenti et al., 2006).  
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 Tumor cell EVs also exhibit decoy functions and interfere with the binding of immune 
molecules to targets. For example, prostate cancer cells generate exosomes containing 
membrane-bound ICAM-1, which binds to LFA-1 on leukocytes to block their adhesion to 
activated endothelial cells (Lee et al., 2010). This prevents immune cell migration into the tissue, 
protecting the tumor. Additionally, the surface of pancreatic cancer cell exosomes is enriched for 
tumor-associated antigens that induce an antibody response as compared to whole cell lysates 
(Capello et al., 2019). These vesicles act as a decoy for antibodies and inhibit complement-
dependent cytotoxicity of pancreatic cancer cells in a dose dependent manner (Capello et al., 
2019). Overall, tumor EVs can bind to immune cell receptors and antibodies, preventing them 
from reaching their intended ligands or targets.  
 Cancer cell EVs also promote apoptosis or inhibit activation of immune cells via 
immunomodulatory molecules, including TGF-b1, Fas ligand (FasL), HLA-G, and PD-L1. For 
example, melanoma cells release EVs containing functional FasL that mediates apoptosis of 
Jurkat T cells (Andreola et al., 2002). Additionally, human cancer cell exosomes inhibit IL-2-
mediated proliferation of peripheral lymphocytes, induce regulatory T cells, and suppress 
natural killer (NK) cell-mediated cytotoxicity (Clayton et al., 2007). These EVs contain TGF-b1, 
and antibody neutralization of this growth factor partially restores lymphocyte proliferation. 
Renal carcinoma cancer stem cells secrete EVs containing HLA-G that inhibit peripheral 
monocyte differentiation into dendritic cells; anti-HLA-G antibody partially blocks this effect 
(Grange et al., 2015). Together, the inability to completely block the inhibitory effects of these 
EVs suggests that they contain other immunomodulatory cargo. Multiple groups have found that 
vesicles modulate immune cells via PD-L1, an immunosuppressive molecule (Chen et al., 2018; 
Dong et al., 2002; Haderk et al., 2017; Poggio et al., 2019). For example, chronic lymphocytic 
leukemia exosomes induce PD-L1 expression in monocytes that can be recapitulated by 
transfer of noncoding Y RNA hY4 and blocked by TLR7 deficiency or TLR signaling inhibition 
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(Haderk et al., 2017). In addition, multiple cancer types release EVs that directly inhibit T cell 
activation and proliferation via PD-L1 (Chen et al., 2018; Poggio et al., 2019; Ricklefs et al., 
2018). The inability to release exosomal PD-L1 inhibits tumor growth in vivo, which can be 
rescued by systemic exosomal PD-L1 (Poggio et al., 2019). Thus, cancer cells use EVs to 
exploit multiple mechanisms for immune suppression and evasion. 
 
Extracellular vesicle functions in immune cells 
 EVs have many other immunomodulatory functions beyond cancer context. Multiple 
groups have studied their role in antigen presentation. Antigen presenting cells (APCs), which 
include dendritic cells and B cells, release 100,000 x g EVs and/or exosomes that contain major 
histocompatibility complex (MHC) class II molecules loaded with peptides and induce antigen-
specific T cell activation in vitro and in vivo (Raposo et al., 1996; Zitvogel et al., 1998). Vesicles 
can present antigens by multiple mechanisms: direct stimulation of T cells; internalization by 
dendritic cells that reload the peptides onto their own MHC class II; or presentation on the 
dendritic cell surface without phagocytosing and processing (Segura et al., 2007; Wakim and 
Bevan, 2011). The latter two mechanisms enhance T cell activation, as recipient dendritic cells 
induce a stronger immune response than EVs alone or the original EV-producing dendritic cells 
(Hao et al., 2007; Montecalvo et al., 2008; Wakim and Bevan, 2011). The differentiation state of 
APCs makes a significant difference in the functionality of their vesicles. Mature dendritic cell 
100,000 x g EVs are 50- to 100-fold more efficient at direct T cell activation than those from 
immature dendritic cells in vitro, and only the former can stimulate T cells in vivo (Segura et al., 
2005). Recently, another group reported a novel form of antigen presentation by perivascular 
dendritic cells that sample the blood. These cells secrete 100,000 x g EVs loaded with 
circulation-derived allergens into the perivascular space, where the vesicles activate mast cells 
and induce anaphylaxis (Choi et al., 2018). Vesicle type influences antigen-presenting activity; 
100,000 x g EVs are more efficient at stimulating antigen-specific T cell activation than 10,000 x 
 13 
g EVs (Wahlund et al., 2017). The antigen-presenting ability of vesicles has important 
implications for allergy, transplantation rejection, and anti-tumor immunity (Admyre et al., 2007; 
Segura et al., 2005; Wolfers et al., 2001; Zitvogel et al., 1998). 
 EVs can also induce immune cell maturation. Mast cell exosomes induce dendritic cell 
maturation and acquisition of antigen-presenting capabilities (Skokos et al., 2003). These EVs 
contain heat shock proteins hsp60 and hsc70, and blocking their receptor CD91 on recipient 
cells prevents dendritic cells from acquiring the ability to present antigens to T cells. 
Additionally, adipocytes release exosome-sized, lipid-filled EVs as an alternative pathway of 
lipid release (Flaherty et al., 2019). These vesicles are taken up by macrophages and induce 
their differentiation, which could induce inflammation.  
 Cytokines and other immunoregulatory molecules can be released on vesicles as a non-
canonical method of secretion. For example, the human THP-1 monocytic cell line releases EVs 
that contain active IL-1b, a proinflammatory cytokine lacking a leader sequence for canonical 
secretion (MacKenzie et al., 2001). Additionally, similarly to cancer EVs, mouse thymic 
exosomes induce Foxp3+ regulatory T cells and suppress proliferation of CD4+ CD25- T cells 
(Wang et al., 2008). Neutralizing TGF-b on these EVs only partially blocks these effects, 
suggesting that they contain other immunomodulatory contents.  
 Furthermore, myeloid cells and stromal cells release EVs with functional forms of 
membrane-bound TNF-a and its family members. Mouse macrophages treated with LPS and 
ATP produce microvesicles that contain membrane-bound TNF-a and cause inflammation in 
vivo (Soni et al., 2019). Multiple groups have associated TNF-a with dendritic cell EV functions. 
Membrane-bound TNF-a on mouse dendritic cell vesicles promotes HUVEC inflammation 
through the NF-kB pathway (Gao et al., 2016). When injected into ApoE-knockout mice, they 
also increase the number of atherosclerotic lesions (Gao et al., 2016). Human LPS-activated 
dendritic cells produce EVs that contain transmembrane TNF receptors, TNFR1 and TNFR2, 
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and soluble TNF-a and induce epithelial cells to secrete inflammatory cytokines, including NF-
kB targets IL-8 and MCP-1 (Obregon et al., 2009). Dendritic cell exosomes trigger tumor cell 
apoptosis and enhance IL-2-activated NK cell production of IFN-g via surface expression of 
TNF-a, TRAIL, and FasL (Munich et al., 2012). In terms of stromal cells, synovial fibroblasts 
from patients with rheumatoid arthritis produce exosomes that contain active, membrane-bound 
TNF-a (Zhang et al., 2006). These vesicles are cytotoxic to L929 cells, a line sensitive to TNF-
a, and can be taken up by anti-CD3-activated T cells to activate AKT and NF-kB signaling and 
delay cell death. Thus, multiple cell types modulate immune cells via EVs.  
 
Extracellular vesicle functions in other pathogenic settings 
 The roles of EVs in fibrosis and aging have recently been reported. For example, 
fibroblasts deficient in NEU1, a sialic acid processing enzyme that negatively regulates 
lysosomal exocytosis, have characteristics of myofibroblasts and produce large quantities of 
exosomes containing high levels of TGF-b and WNT signaling molecules (van de Vlekkert et al., 
2019). These EVs upregulate pro-fibrotic genes in normal fibroblasts and convert them into 
myofibroblasts, thus propagating fibrotic disease.  
 In terms of aging, senescent fibroblasts induce paracrine senescence via 100,000 x g 
EVs, a phenotype that can be partially blocked by IFITM3 depletion in the donor cells and their 
vesicles (Borghesan et al., 2019). Together, these findings reinforce the concept that EVs have 
functions in a wide variety of cell types and diseases. 
 
Extracellular vesicle functions in reproductive tissues 
 Given my work on the role of CTB EVs in reproduction, in this and subsequent sections, 
I focus on studies that employed human samples. Bodily fluids produced by reproductive organs 
are rich in EVs. These include semen, follicular fluid, and endometrial fluid (Campoy et al., 
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2016; Franz et al., 2016; Hoog and Lotvall, 2015). Both paternal and maternal vesicles play 
important roles in reproduction. In terms of the former, EVs from seminal fluid target both sperm 
and maternal cells. These vesicles are likely important for sperm motility, as seminal fluid EVs 
isolated from men with normal sperm function increases sperm motility whereas those from 
asthenozoospermic men do not (Murdica et al., 2019). Multiple groups have described functions 
of these vesicles in the uterus. Human seminal fluid EVs induce endometrial stromal cell 
secretion of IL-6 and IL-8, two cytokines involved in implantation (Paktinat et al., 2019). These 
EVs likely also play a role in suppressing uterine immune cells. Human seminal fluid 100,000 x 
g EVs inhibit proliferation of activated human peripheral blood mononuclear cells (PBMCs) 
(Kelly et al., 1991). These vesicles are taken up by human neutrophils and monocytes, reducing 
their ability to phagocytose latex beads (Skibinski et al., 1992). Additionally, human seminal fluid 
exosomes increase antigen-presenting cell production of indoleamine 2,3 deoxygenase, which 
is known to inhibit T cells (Vojtech et al., 2019). Overall, seminal EVs improve sperm motility, 
promote implantation, and suppress the maternal immune system, all processes required for 
pregnancy. 
There are only a few studies on ovarian follicle EVs and their effects on oocytes. On a 
practical level, obtaining follicular fluid requires a much more invasive procedure compared to 
collecting semen. Human follicular fluid contains EVs enriched for miRNAs that target genes 
that suppress follicle maturation and resumption of meiosis, suggesting that these vesicles 
promote oocyte development (Franz et al., 2016; Santonocito et al., 2014).  
Uterine fluid contains EVs that likely play a role in implantation (Campoy et al., 2016). 
Most studies have focused on endometrial epithelial cells. For example, 100,000 x g EVs from 
the human endometrial epithelial cell line ECC-1 contain miRNAs that target genes in pathways 
involved with implantation (Ng et al., 2013). Multiple groups have found that these EVs promote 
trophectoderm adhesion and migration. ECC-1 EVs are taken up by and increase the adhesive 
capacity of the HTR8 trophoblast cell line (Greening et al., 2016). Additionally, EEC-1 EVs 
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increase the invasion and adhesion of trophoblast stem cell-derived trophectoderm (Zdravkovic 
et al., 2015) cultured as spheroids to mimic blastocysts (Evans et al., 2019). In terms of primary 
cells, human endometrial epithelial cells secrete 120,000 x g EVs that are internalized by the 
trophectoderm of mouse embryos (Vilella et al., 2015). These vesicles contain maternal miRNA 
has-miR-30d, which upregulates gene expression of adhesion molecules and increases 
blastocyst attachment (Vilella et al., 2015). Uterine immune cells likely support implantation as 
well. For example, PMA-stimulated THP-1 monocyte-derived macrophage 100,000 x g EVs are 
taken up by the BeWo choriocarcinoma cell line and by vaginally-delivered term placental villi in 
an ex vivo explant model, in which they promote secretion of inflammatory cytokines IL-6 and 
IL-8 and immunosuppressive IL-10 (Holder et al., 2016). Thus, a variety of EVs promote 
reproduction and implantation. 
 
Placental extracellular vesicle functions in normal pregnancies 
 The placenta produces large numbers of EVs that increase in concentration throughout 
gestation (Germain et al., 2007; Knight et al., 1998; Salomon et al., 2014; Sarker et al., 2014). 
The component processes of human placentation have many parallels with tumorigenesis and 
metastasis. Cytotrophoblasts invade the uterus, breach the vasculature, and modulate the 
maternal immune system to promote tolerance of the feto-placental unit (Hemberger, 2013; 
Maltepe and Fisher, 2015). The functions of placental EVs likely mirror those of cancer vesicles, 
mediating a variety of physiologic and immunologic adaptations at near and distant sites in 
normal pregnancy. 
 Many studies isolate placental EVs from the maternal circulation or from immortalized 
cell lines. These models are problematic and have many limitations. EVs isolated from blood are 
contaminated by high density lipoproteins and vesicles from non-placental sources (Aatonen et 
al., 2017; Yuana et al., 2014). Placental vesicles quickly aggregate with and activate platelets, 
stimulating their release of EVs, which make up the majority of blood-borne vesicles (Aatonen et 
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al., 2017; Tannetta et al., 2015). Functional effects observed in studies using circulating EVs 
could be due to placental vesicles or platelet-derived EVs influenced by placental signals.   
 Choriocarcinoma and immortalized placental cell lines are poor mimics of primary CTBs 
and STBs. In terms of epigenetics, choriocarcinoma lines JAR, JEG-3, and BeWo and 
transformed trophoblastic HTR-8/SVneo cells have DNA hypermethylation patterns that are 
more typical of cancer cells than primary CTBs (Novakovic et al., 2011). Immortalized TEV-1 
and SWAN71 cell lines have methylation patterns similar to each other but distinct from primary 
cells (Novakovic et al., 2011). Choriocarcinoma and transformed trophoblast cell lines also 
variably express primary CTB markers. For example, JAR and HTR-8/SVneo cell lines do not 
express the CTB marker HLA-G, whereas BeWo cells variably express this molecule 
(Novakovic et al., 2011). In addition, trophoblastic cell lines are functionally impaired in terms of 
adhesion, migration, and invasion (Hannan et al., 2010). Since choriocarcinoma and 
transformed cell lines poorly phenocopy CTBs, the EVs they produce are less functionally 
relevant than primary placental vesicles.   
Early studies of primary placental EVs focused on the subset generated by STBs. The 
authors compared vesicles collected by ultracentrifugation after generation by three methods: 
mechanically fractured from chorionic villi, isolated from the medium in which explants were 
cultured, and captured from placental perfusate (Gupta et al., 2005b; Smarason et al., 1993). 
Each method produced EVs that were morphologically similar but functionally different (Gupta et 
al., 2005b). For example, STB EVs from all the methods inhibit HUVEC proliferation, but only 
those isolated by mechanical means disrupt the cells’ morphology and induce apoptosis in vitro 
(Gupta et al., 2005b; Smarason et al., 1993).  
The method by which they were generated affects the immunomodulatory activity of STB 
EVs. Vesicles derived mechanically and from explant cultures inhibit peripheral T cell activation, 
proliferation, and secretion of IL-2 and IFN-g; EVs derived from perfusion promote T cell 
proliferation and increase IFN-g secretion (Gupta et al., 2005a). Explant-derived STB EVs also 
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carry FasL and TRAIL and induce Jurkat T cell apoptosis (Stenqvist et al., 2013). Similarly, 
perfusion-derived STB EVs activate PBMCs, are taken up by monocytes and B cells, and 
stimulate production of inflammatory cytokines (Germain et al., 2007; Southcombe et al., 2011). 
Also, STBs EVs from explants and perfused placentas induce peripheral monocyte secretion of 
inflammatory cytokines, whereas mechanically-derived vesicles do not (Messerli et al., 2010).  
Of the three methods, the placental perfusion model is the most physiologically relevant 
and has the additional advantage of allowing for high yields of STB EVs (Dragovic et al., 2015; 
Southcombe et al., 2011). More recent studies using this method describe non-immune 
functions of these vesicles, such as inducing platelet activation and aggregation (Tannetta et al., 
2015).  
Studies of primary CTB EVs have focused on those derived from term placentas. In 
general, the vesicles have immunomodulatory roles. For example, term cytotrophoblast 
exosomes confer viral resistance to recipient non-placental cells, including HUVECs, human 
uterine microvascular endothelial cells (HUtMVECs), placental fibroblasts, and foreskin 
fibroblasts (Delorme-Axford et al., 2013; Ouyang et al., 2016). This is likely due to miRNAs from 
the placenta-specific chromosome 19 cluster (C19MC), which are found in trophoblasts and 
their vesicles (Donker et al., 2012). Transfection of this cluster into recipient cells also 
attenuates viral replication (Delorme-Axford et al., 2013). Additionally, primary term villous 
cytotrophoblast 100,000 x g EVs suppress secretion of Th1 cytokines IL-2, TNF-a, and IFN-g in 
activated Jurkat T cells and PBMCs; this activity is blocked by inhibition of syncytin-2 (Lokossou 
et al., 2019). The function of CTB EVs earlier in pregnancy has not been studied. 
 
Placental extracellular vesicle functions in complicated pregnancies 
 Failure of the placenta to mediate integration of the embryo/fetus with the mother results 
in pregnancy complications and is associated with abnormal EV production. For example, 
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preeclampsia, which is characterized by shallow CTB invasion and reduced maternal spiral 
artery remodeling (Ball et al., 2006; Fisher, 2015), is associated with higher levels of circulating 
placental EVs (Germain et al., 2007; Knight et al., 1998; Lok et al., 2008). Perfusion-derived 
STB EVs from preeclamptic and normal placentas differ in contents and function. For example, 
in preeclampsia, STB EVs contain increased levels of Flt-1 and the percentage of endoglin-
containing vesicles decreases (Tannetta et al., 2013). These anti-angiogenic molecules may 
contribute to the perturbation of maternal vasculature responses that is the hallmark of this 
pregnancy complication (Tannetta et al., 2013). These EVs also contain reduced levels of the 
vasodilators, endothelial nitric oxide synthase and nitric oxide (Motta-Mejia et al., 2017). 
Additionally, STB EVs have an increased ability to activate platelets (Tannetta et al., 2015). 
Overall, it is unclear whether vesicles contribute to the pathology of the disease or are due to 
compensation by the placenta.  
 In terms of distant physiologic changes, in normal pregnancy, the mother becomes 
insulin resistant, which facilitates glucose transfer to the developing embryo/fetus (Lain and 
Catalano, 2007). To compensate, the maternal pancreas expands in size and increases insulin 
secretion (Baeyens et al., 2018). If this organ fails to adapt, then the mother develops 
gestational diabetes mellitus (Rieck and Kaestner, 2010). The mechanisms remain unknown but 
may be due to abnormalities in placental vesicle production or contents. STB EVs contain active 
dipeptidyl peptidase IV (DPPIV), which breaks down GLP-1, a regulator of glucose-dependent 
insulin secretion (Kandzija et al., 2019). In gestational diabetes, the concentration of DPPIV-
containing EVs increases, which could be related to the reduced insulin secretion that 
characterizes this disorder (Kandzija et al., 2019). Investigating maternal adaptation to normal 
pregnancy may provide insights into mechanisms underlying pregnancy complications. 
  
 20 
 
Figure 1.1 The placenta forms the maternal-fetal interface. 
The placenta is composed of two types of villi, floating and anchoring. The multinucleated 
syncytium forms the villous surface and is bathed in maternal blood. Progenitor CTBs lie beneath 
the STB layer. These cells fuse to form the syncytium or invade from anchoring villi into the 
decidua, where they remodel spiral arteries. Invasive CTBs are in direct contact with decidual 
immune cells, including macrophages and lymphocytes, and uterine cells, such as decidualized 
endometrial stromal fibroblasts. 
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Figure 1.2 Exosomes and microvesicles originate from different cellular compartments.  
Exosomes originate in the endosomal compartment, where inward budding forms multivesicular 
bodies (MVBs). MVBs are transported to the cell surface, where they fuse with the plasma 
membrane, releasing exosomes into the extracellular space. Microvesicles are formed by 
shedding from the plasma membrane.  
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Cytotrophoblasts produce extracellular vesicles  
We isolated two populations of EVs from the conditioned medium of second trimester 
cytotrophoblasts (CTBs) by ultracentrifugation (Figure 2.1). Because the source was primary 
CTBs, the limited amount of material precluded additional purification steps, such as density 
gradient centrifugation and/or immuno-affinity isolation. We expected the 16,500 x g EV pellet to 
be enriched for microvesicles and the 100,000 x g EV pellet to be enriched for exosomes. 
Transmission electron microscopy (TEM) revealed that the 16,500 x g pellet was comprised of a 
heterogenous population that included larger, crenulated vesicles and smaller exosome-like 
EVs (Figure 2.2). They were a heterogenous population, with 61% under 150 nm. In contrast, 
the 100,000 x g pellet was enriched for vesicles with a cup-like morphology typical of exosomes 
(Figure 2.3). These EVs were mainly smaller EVs, with 86% under 150 nm. As microvesicles 
and exosomes overlap in size, this heterogeneity and overlap in vesicle size was expected for 
EVs isolated by ultracentrifugation.  
 
Cytotrophoblast extracellular vesicles contain exosomal and placenta-specific markers 
Initially, we used immunoblotting methods to compare the protein contents of 16,500 x g 
and 100,000 x g EVs to CTB lysates. With regard to exosomal markers, the tetraspanin CD9, 
was only detected in the 100,000 x g EVs (Figure 2.4), which were also enriched for the 
ESCRT-0 component, HRS (Figure 2.5), compared to the 16,500 x g fraction. This was 
consistent with the TEM results, reinforcing the conclusion that 100,000 x g pellet was enriched 
for exosomes and the 16,500 x g pellet was a heterogenous population that also contained 
these vesicles.  
With regard to placenta-specific markers, we were interested in whether these EVs 
contained the human trophoblast-specific nonclassical MHC class I molecule, HLA-G (McMaster 
et al., 1995). As expected, CTB lysates primarily expressed the monomeric form (Figure 2.6), 
which appeared as a diffuse band due to the complex glycosylation this protein carries 
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(McMaster et al., 1998). The 16,500 x g EVs contained both the monomer and dimer, in an 
approximate ratio of 3:1. In comparison, the 100,000 x g EVs were significantly enriched for 
both forms of the molecule compared to the lysate and 16,500 x g EVs, which were present in 
an approximate ratio of 3:2. Importantly, dimerized HLA-G has a higher affinity for its receptors, 
LILRB1 and LILRB2, suggesting enhancement of inhibitory signaling (Shiroishi et al., 2006). 
Placenta alkaline phosphatase (PLAP) had a similar expression pattern, with significant 
expression in the 100,000 x g EVs versus CTB lysate (Figure 2.7).   
We looked for other molecules whose functions in exosomes are relevant to the biology 
of pregnancy. Placental EVs contained the ECM molecule, fibronectin (Figure 2.8), whose 
expression was 16-fold higher in 100,000 x g EVs compared to the 16,500 x g fraction. Previous 
studies show that the exosomal form of this molecule promotes migration speed in an autocrine 
manner (Sung et al., 2015; Sung and Weaver, 2017). Exosomal PD-L1 suppresses T cell 
activation in cancer (Poggio et al., 2019). As immune evasion is critical for cancer progression 
and pregnancy success, we asked whether CTB EVs contained this molecule. PD-L1 was 
detected in CTB lysate and both populations of vesicles (Figure 2.9), suggesting that these EVs 
have immune function.  
 
Global proteomic analysis of cytotrophoblast extracellular vesicles 
 We performed mass spectrometry profiling of the protein contents of second trimester 
CTB EVs. We found 811 proteins in 16,500 x g EVs and 427 proteins in 100,000 x g EVs 
(Figure 2.10). Of those identified, 377 were components of both vesicle types, 434 were unique 
to the 16,500 x g fraction, and 50 were found only in the 100,000 x g pellet. More proteins may 
have been identified in the 16,500 x g sample due to EV heterogeneity or the larger size of the 
vesicles. 
 Multiple exosomal markers were detected in CTB EVs: CD9 and CD81 were identified in 
both vesicle types, whereas CD63, TSG101, and CD82 were only found in the 100,000 x g 
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fraction (Raposo and Stoorvogel, 2013). In both EV populations, we identified molecules with 
immune functions, including CD47, CD59, CD276, lactate dehydrogenase, and Galectin-3. 
Additionally, HLA-G was only detected in the 100,000 x g pellet, reflecting the enrichment of this 
molecule observed by immunoblot (Figure 2.6). Both EV types contained multiple proteasome 
subunits, which process antigens for peptide presentation by HLA molecules (Vigneron et al., 
2017), suggesting that this process might be occurring.  
 Both fractions had proteins involved in iron transport, such as HLA-H, transferrin 
receptor protein 1, and serotransferrin (Garrick, 2011; Pascolo et al., 2005). We also detected 
proteins previously associated with placental EVs, such as retrotransposon-derived protein 
PEG10, endoglin, DPPIV, and trophoblast glycoprotein (Abed et al., 2019; Alam et al., 2018; 
Kandzija et al., 2019; Tannetta et al., 2013). Both vesicle types contained multiple CTB 
adhesion-related molecules: fibronectin; Eph family members; integrins a1, a5, a6, b1, and b4; 
and laminin subunits (Damsky and Fisher, 1998; Red-Horse et al., 2005). In other systems, 
these molecules are critical for vesicles homing to target cells (Hoshino et al., 2015). We also 
detected components of prostaglandin pathways, including 15-hydroxyprostaglandin 
dehydrogenase, prostaglandin E synthase 3, and prostaglandin F2 receptor negative regulator. 
Additionally, CTB EVs contained proteins with cancer functions that reflect placental processes: 
neuroblast differentiation associated protein AHNAK, present in both vesicle populations, 
promotes tumor migration, invasion, and EV release (Shankar et al., 2010; Silva et al., 2016), 
whereas glia-derived nexin, detected in the 100,000 x g fraction, mediates tumor vascular 
mimicry (Wagenblast et al., 2015). Overall, the EV proteome contained a multitude of proteins 
with diverse functions. 
 The proteome of each vesicle type was matched to GO terms. Significance was greater 
for 16,500 x g pathways compared to that of 100,000 x g, likely due to the fact they contained 
approximately twice the number of proteins. The top biological processes that were represented 
by EV contents mainly fell into 3 categories: localization and transport, viral pathways, and 
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metabolism (Figure 2.11). Viral processes were likely represented due to many proteins in these 
pathways with membrane budding functions. Vesicle-mediated transport, antigen processing 
and presentation, and regulation of RNA stability were also represented.  
 
Discussion 
 Here we characterize second trimester CTB EVs by TEM, immunoblot, and mass 
spectrometry. The 16,500 x g fraction was a heterogeneous population, while the 100,000 x g 
fraction was enriched for vesicles with the size and morphology of exosomes. Additionally, the 
100,000 x g pellet was enriched for exosomal marker CD9, and both EV populations was 
enriched for placental markers HLA-G and PLAP. In terms of proteome profiling, we detected a 
multitude of proteins with diverse functions in CTB EVs, including exosomal markers.  
The interior of 100,000 x g EVs is a non-reducing environment, in which protein 
disulfide-isomerases catalyze formation of disulfide bonds and multimerization of molecules, 
which can enhance their activity (Bulleid and Ellgaard, 2011; Lynch et al., 2009). As compared 
to the cytoplasm, these vesicles contain lower levels of glutathione, which prevents formation of 
these bonds (Lynch et al., 2009). Other groups have found dimerized molecules in vesicles—a 
human EBV-transformed B cell line produces 100,000 x g EVs enriched for dimerized classical 
MHC class I molecules (Lynch et al., 2009). Mouse neuraminidase 1-null myofibroblasts secrete 
exosomes containing TGF-b1 dimers (van de Vlekkert et al., 2019). In the study described here, 
we detected multiple protein disulfide-isomerases in both CTB EV types by mass spectrometry, 
suggesting that they promote dimerization of vesicular proteins. Immunoblotting for HLA-G 
demonstrated that CTB EVs are enriched for a reactive band consistent in size with the dimeric 
form of this molecule (Figure 2.6). Dimerization of this CTB MHC class I molecule increases its 
affinity for the inhibitory receptor LILRB1 and LILRB2 and, consequently, its signaling strength 
(Boyson et al., 2002; Kovats et al., 1990; Shiroishi et al., 2006; Yelavarthi et al., 1991). 
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Furthermore, CTB HLA-G is heavily glycosylated with polylactosamine chains, which are 
composed of N-acetylglucosamine-galactose dimers (McMaster et al., 1998). These residues 
are recognized by CD206, an inhibitory mannose receptor present on decidual macrophages 
(Co et al., 2013). An individual and a first trimester placenta homozygous for a null mutant allele 
for HLA-G have been reported, suggesting that this MHC class I molecule is not essential for 
reproduction (Ober et al., 1998). However, other mutations in the promoter and untranslated 3’ 
regions of HLA-G are associated with negative pregnancy outcomes, such as miscarriage rates 
and preeclampsia (Ober et al., 2003; Yie et al., 2008). Thus, CTB EV expression of dimeric 
HLA-G may be one of many mechanisms that contribute to maternal tolerance to the fetus.  
 
Materials & Methods 
Tissue collection 
 The University of California, San Francisco (UCSF) Institutional Review Board approved 
this study. All donors gave informed consent. Second trimester placentas were collected 
immediately following elective terminations and placed in cytowash medium, containing DME/H-
21, 12.5% fetal bovine serum (Hyclone), 1% glutamine plus, 1% penicillin and streptomycin, and 
0.1% gentamicin. Tissue samples were placed on ice prior to dissection. 
Isolation and culture of human primary cytotrophoblasts 
 CTBs were isolated from second trimester human placentas as previously described 
(Hunkapiller and Fisher, 2008). Single cells were counted using a hemocytometer and 
immediately plated on Matrigel (BD Biosciences)-coated 6-well plates in 1.5 ml serum-free 
medium containing DME/H-21, 2% Nutridoma-SP (Roche), 1% sodium pyruvate, 1% HEPES 
buffer, 1% glutamine plus (Atlanta Biologicals), 1% penicillin and streptomycin, and 0.1% 
gentamicin. CTBs were cultured at a density between 8x105 and 1.5x106 cells/well. CTBs were 
incubated at 37°C in 5% CO2, 95% air. After 1 h, the medium with unattached immune and 
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other cells was removed and replaced with another 3 ml serum-free medium before returning 
the cells to the incubator.  
Isolation of extracellular vesicles 
EVs were isolated by differential centrifugation at 4°C by using published methods 
(Thery et al., 2006). After culturing for 36-38 h, conditioned medium was centrifuged at 400 x g 
for 5 min to pellet the cells. The supernatant was sequentially centrifuged at 2,000 x g and 
16,500 x g, each for 20 min. The liquid fraction was passed through a 0.22 µm filter prior to 
ultracentrifugation at 100,000 x g for 70 min. The supernatant was removed by aspiration. The 
16,500 x g and 100,000 x g pellets were resuspended in 35 ml phosphate buffered saline (PBS) 
and re-centrifuged under the original conditions with which they were collected. The pellet was 
isolated by aspiration of the liquid phase. Typically, 5 µl were aliquoted to determine the protein 
concentration and the remaining 70 µl were used in experiments. Both aliquots were stored at -
80°C. Samples for protein determinations were lysed in an equivalent volume of buffer 
containing 100 mM ammonium bicarbonate and 0.2% SDS. Quantitation was accomplished by 
using a Micro BCA Protein Assay kit (Thermo Scientific Pierce).  
Transmission electron microscopy 
Transmission electron microscopy (TEM) was performed as previously described (Thery 
et al., 2006). In brief, EVs were adsorbed onto a glow discharged 400 mesh Formvar-coated 
copper grid (Electron Microscopy Sciences) for 1 min. Samples were negatively stained by 
dipping four times in 1% aqueous uranyl acetate. Excess liquid was blotted with filter paper. 
Grids were air dried and imaged in a Tecnai 12 transmission electron microscope (Field 
Electron and Ion Company). EV diameter was measured using ImageJ. 
Immunoblotting 
EVs or cell lysates were lysed as described above. For all targets, 2 µg protein was 
dissolved under non-reducing conditions with NuPAGE LDS Sample Buffer (Invitrogen). 
Samples were boiled for 10 min, separated on a NuPAGE 4-12% Bis-Tris gel (Invitrogen), and 
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transferred to a 0.45 µm nitrocellulose membrane (Bio-Rad). Blocking was accomplished with 
5% powdered nonfat dry milk reconstituted in PBS-T (0.1% Tween in PBS). Membranes were 
incubated in primary antibody diluted in blocking buffer at 4°C overnight. The isotype, dilution, 
and source for each of the primary and secondary antibodies are summarized in Table 2.1. 
Immunoreactive bands were visualized with ECL2 Western blotting substrate (Thermo Scientific 
Pierce) and Amersham Hyperfilm ECL (GE Healthcare). 
Proteomics 
 EV samples were lysed as described above. Lysates were prepared that contained a 
minimum of 25 µg protein, sometimes achieved by pooling samples. Samples were reduced 
with tris(2-carboxyethyl) phosphine hydrochloride (TCEP) added to a final concentration of 5 
mM in lysis buffer at 60°C for 1 h and immediately alkylated with freshly prepared 
iodoacetamide (IAA) at a final concentration of 10 mM for 15 min at room temperature. 
Digestion was performed by incubating samples overnight with 3 µg sequencing grade trypsin 
(Promega) at 37°C. SDS was removed with 2 ml Detergent Removal Columns (Pierce). 
 Sequential Window Acquisition of All Theoretical Mass Spectra (SWATH-MS) was 
performed as previously described (Collins et al., 2017). Peptides were separated by reversed 
phase nanoLC (Sciex) immediately followed by mass spectrometry analysis on a TripleTOF 
5600 (Sciex) using data-independent acquisition.  
 Proteins were identified and quantified using Spectronaut and the pan-human spectral 
library. Redundancies were collapsed according to number of total peptides. We used DAVID to 
perform functional enrichment of Gene Ontology (GO) Biological Processes (Level 4) of the EV 
proteomes as defined by gene symbols (Huang et al., 2007). 
Statistics 
Statistical analyses were performed using SPSs version 24 (IBM). Immunoblot 
densitometry measurements were analyzed using a one-way ANOVA with Dunnett’s test.  
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Figure 2.1 Schematic of primary human cytotrophoblast (CTB) and EV isolation 
Each placenta was mechanically dissected into chorionic villi. Cells were separated from the 
tissue by 4 enzymatic digestion steps. A Percoll density gradient enriched for CTBs, which were 
plated on Matrigel in a 6-well plate with serum-free medium. Medium was changed after 1 h to 
remove dead or non-adherent cells. After ~38 h cell culture, the conditioned medium was removed 
for EV isolation by differential (ultra)centrifugation. Dead cells were pelleted at 400 x g. The 
supernatant was centrifuged at 2000 x g to remove apoptotic bodies. EVs were pelleted from the 
supernatant at 16,500 x g. After filtering with a 0.22 µm filter, the supernatant was ultracentrifuged 
at 100,000 x g to collect another population of EVs. Both sets of vesicles were resuspended in 
PBS and re-pelleted at the original isolation speeds.  
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Figure 2.2 TEM of the CTB 16,500 x g pellet revealed a heterogenous vesicle population. 
Transmission electron microscopy (TEM) of the 16,500 x g fraction demonstrated that they are a 
heterogeneous population comprised of a heterogenous population that included larger, 
crenulated vesicles and smaller exosome-like EVs (left panel; scale bar = 200 nm). A histogram 
of CTB 16,500 x g EV sizes showed a range of sizes, with most vesicles (61%) under 150 nm 
(right panel). n=3 biological replicates, 2 independent experiments.  
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Figure 2.3 The CTB 100,000 x g fraction was enriched for EVs with exosomal size and 
morphology by TEM. 
TEM revealed that the 100,000 x g pellet was enriched for vesicles with a cup-like morphology 
typical of exosomes (left panel; scale bar = 200 nm). A histogram of this fraction showed that it 
was composed of mainly smaller EVs, with the majority (86%) under 150 nm (right panel). n=3 
biological replicates, 2 independent experiments.   
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Figure 2.4 CTB 100,000 x g EVs were enriched for CD9. 
Immunoblots comparing CTB lysate, 16,500 x g EVs, and 100,000 x g EVs were stained for the 
exosomal marker CD9. A representative blot is shown. Relative intensity was measured by 
densitometry. The 100,000 x g fraction was enriched for CD9. n=5 biologic replicates, each 
performed independently. **** p<0.001. 
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Figure 2.5 CTB EVs contained HRS. 
Immunoblots comparing CTB lysate, 16,500 x g EVs, and 100,000 x g EVs were stained for the 
ESCRT-0 component HRS. A representative blot is shown. Relative intensity was measured by 
densitometry. n=5 biologic replicates, each performed independently. No significant difference in 
expression was calculated. 
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Figure 2.6 CTB 100,000 x g EVs were enriched for monomeric and dimeric HLA-G. 
Immunoblots comparing CTB lysate, 16,500 x g EVs, and 100,000 x g EVs were stained for HLA-
G, a CTB marker. Two bands were detected, consistent in size with the monomeric and dimeric 
forms of the molecule. A representative blot is shown. Relative intensities were measured by 
densitometry. The 16,500 x g pellet was enriched for the dimer compared to cell lysate. The 
100,000 x g fraction was enriched for both forms of the molecule. n=5 biologic replicates, each 
performed independently. * p<0.05, ** p<0.01, *** p<0.005, **** p<0.001. 
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Figure 2.7 CTB EVs were enriched for placental alkaline phosphatase (PLAP). 
Immunoblots comparing CTB lysate, 16,500 x g EVs, and 100,000 x g EVs were stained for the 
placental marker PLAP. A representative blot is shown. Relative intensity was measured by 
densitometry. Both EV populations were enriched for PLAP. n=5 biologic replicates, each 
performed independently. * p<0.05, *** p<0.005. 
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Figure 2.8 CTB 100,000 x g EVs were enriched for fibronectin (FN) compared to the 
16,500 x g fraction. 
Immunoblots comparing CTB lysate, 16,500 x g EVs, and 100,000 x g EVs were stained for FN. 
A representative blot is shown. Relative intensity was measured by densitometry. The 100,000 x 
g fraction was enriched for FN compared the 16,500 x g pellet. n=5 biologic replicates, each 
performed independently. *** p<0.005. 
  
 38 
 
Figure 2.9 CTB EVs contained PD-L1. 
Immunoblots comparing CTB lysate, 16,500 x g EVs, and 100,000 x g EVs were immunostained 
for PD-L1. A representative blot is shown. Relative intensity was measured by densitometry. PD-
L1 was detected in CTB EVs. n=5 biologic replicates, each performed independently.  
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Figure 2.10 Venn diagram of proteins identified by mass spectrometry profiling showed 
that CTB EV contents overlapped. 
Mass spectrometry profiling detected 811 proteins in CTB 16,500 x g EVs and 427 proteins in 
CTB 100,000 x g EVs. Of the identified proteins, 377 were shared between both populations, 434 
were unique to the 16,500 x g pellet, and 50 were only found in the 100,000 x g fraction. 
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Figure 2.11 CTB EV proteomes were enriched for proteins in a variety of GO Biological 
Processes. 
The proteome of each vesicle type was matched to GO terms. The most significant 25 Biological 
Processes for each EV type are presented here and mainly fell into 3 categories: localization and 
transport, viral pathways, and metabolism. Cellular organization, antigen processing and 
presentation, and regulation of RNA stability were also represented.   
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Table 2.1 Antibodies for immunoblotting 
Primary Antibodies Secondary Antibodies 
Target Clone Supplier Catalog # Host Dilution Antibody Conjugate Supplier Dilution 
CD9 KMC8 
BD 
Biosciences BDB553758 rat 1:250 
Donkey 
anti-rat Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
FN 
Clone 10/ 
Fibronectin 
BD 
Biosciences 610077 mouse 1:1000 
Donkey 
anti-
mouse Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
HLA-G 4H84 
Laboratory of 
S.J. Fisher N/A mouse 1:250 
Donkey 
anti-
mouse Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
HRS D7T5N 
Cell Signaling 
Technology 15087 rabbit 1:1000 
Donkey 
anti-
rabbit Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
PD-L1 E1L3N 
Cell Signaling 
Technology 13684 rabbit 1:1000 
Donkey 
anti-
rabbit Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
PLAP EPR6141 
Millipore 
Sigma MABC644 rabbit 1:750 
Donkey 
anti-
rabbit Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
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Cytotrophoblast 100,000 x g extracellular vesicles contain TNF-a 
 Given that proteins with immune functions were represented in CTB EVs, we performed 
a cytokine array (Luminex High Sensitivity T Cell panel) to identify cargo that may be present at 
biologically active concentrations too low to be detected by mass spectrometry. In these 
experiments, we compared the contents of CTB 16,500 x g and 100,000 x g EVs. As a control 
for placenta-specific vesicle functions, we included 100,000 x g EVs from the K562 
erythroleukemic cell line, which have been shown to abundantly produce vesicles (Rivoltini et 
al., 2016; Savina et al., 2002). Most analytes were below the threshold of detection, but low 
levels of IL-6 (~0.2 pg/µg; p<0.05) and MIP-3a (~1 pg/µg; p<0.001) were detected in the 
100,000 x g EV fraction (Figure 3.1). In contrast, only the CTB 100,000 x g EVs contained 
relatively high levels of TNF-a (~5 pg/µg protein; p<0.001; Figure 3.2).  
To confirm this finding, we immunoblotted CTB EVs with anti-TNF-a. The 100,000 x g 
fraction had a band with an estimated molecular weight of 70 kDa (Figure 3.3), which was 
consistent with the trimeric membrane form of this molecule (Kriegler 1988; Tang, 1996). 
Previous studies have shown that this multimer has the highest activity (Tang, 1996). We also 
examined CTB TNF-a expression in situ. Immunolocalization at the maternal-fetal interface 
showed expression among cytokeratin-positive CTBs in both villous (data not shown) and 
invasive cells (Figure 3.4).   
 
Cytotrophoblast extracellular vesicles induce decidual cell transcription and secretion of 
cytokines 
Previous work showed CTB conditioned medium amplifies decidual cell expression and 
secretion of angiogenic and immune-modulating factors (Hess et al., 2007). Specifically, gene 
ontology suggested the mechanism involved activation of the NF-kB cascade. The 
consequences included increased decidual cell secretion of downstream targets CXCL1/GRO1 
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and CXCL8/IL-8. Given that exosomal TNF-a activates NF-kB signaling in target cells, including 
fibroblasts and T cells (Zhang et al., 2006), we asked whether TNF-a-containing CTB 100,000 x 
g EVs induced expression and secretion of NF-kB targets in decidualized endometrial stromal 
fibroblasts (dESFs) over a 24 h culture period (Figure 3.5). As in the cytokine analyses above, 
100,000 x g EVs from the K562 cell line were used as a control.  
 Changes in gene expression were measured with a chip-based qRT-PCR method 
(Fluidigm). Of the target genes measured, 12 mRNAs were significantly upregulated by CTB 
100,000 x g EVs compared to PBS over the course of the experiment with the most significant 
changes at 3 h (Figure 3.6). Upregulated genes included CXCL8 (IL-8), IL6, CXCL1 (GRO), 
CCL2 (MCP-1), CSF1, ICAM1, NFKB1, NFKB2, RELB, TNFAIP2, and TNFAIP3, which are 
known targets of NF-kB activation (Anisowicz et al., 1991; Brach et al., 1991; Bren et al., 2001; 
Hohensinner et al., 2007; Kang et al., 2007; Kunsch and Rosen, 1993; Libermann and 
Baltimore, 1990; Lombardi et al., 1995; Son et al., 2008; Ten et al., 1992; Ueda et al., 1994; van 
de Stolpe et al., 1994; Zhou et al., 2003). Compared to the PBS control, treatment with CTB 
100,000 x g EVs increased mRNA levels of CXCL8 by 4.8-fold (Figure 3.7), IL6 by 2.8-fold 
(Figure 3.8), CXCL1 by 5.2-fold (Figure 3.9), and CCL2 by 5.4-fold (Figure 3.10) at the 3 h time 
point. CTB 16,500 x g EV treatment increased mRNA levels of LIF and most NF-kB targets 
upregulated by the 100,000 x g fraction at 3h. K562 100,000 x g EVs did not significantly 
change mRNA levels of target genes. Transcription returned to levels not significantly different 
from PBS control at 12 and 24 h.  
 We calculated that EVs in the above experiments contained ~10 pg of TNF-a based on 
the data shown in Figure 3.2. To determine whether this cytokine alone could recapitulate the 
effects of CTB 100,000 x g EVs, we treated dESFs with the recombinant version of this 
molecule (rhTNF-a) at an equivalent concentration and a 10-fold lower amount over the course 
of 24 h. A 10-fold higher concentration was omitted due to obvious cell death. The 
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transcriptional response was similar to that of CTB 100,000 x g EV treatment, but upregulation 
of NF-kB target genes was sustained at each time point (Figure 3.11). In particular, rhTNF-a 
increased mRNA levels of NF-kB targets CXCL8 (Figure 3.12), IL6 (Figure 3.13), CXCL1 
(Figure 3.14), CCL2 (Figure 3.15), CSF1, ICAM1, NFKB1, NFKB2, RELB, TNFAIP2, TNFAIP3, 
EGFR, and JUNB. There was no significant difference between the two doses of rhTNF-a 
studied. Overall, the number, magnitude, and duration of transcriptional changes were greater in 
dESFs treated with an equivalent concentration of rhTNF-a compared to CTB EV treatment, 
likely because these vesicles contain other molecules that constrain the response to this 
cytokine.  
 To extend the RNA data, we performed a Luminex cytokine array for upregulated 
targets. Compared to PBS controls, CTB 100,000 x g EVs increased dESF secretion of a 
number of chemokines and cytokines. However, the kinetics were different for each analyte. 
Levels of CXCL8/IL-8 increased at each time point, with the most significant effects at 3 and 12 
h (Figure 3.16). Similarly, CTB 100,000 x g EVs increased CXCL1/GRO secretion, particularly 
at 3 h (Figure 3.17). In contrast, their effects on CCL2/MCP-1 peaked at 12 h (Figure 3.18). EV-
induced IL-6 secretion did not significantly change at any individual time point, but, in the 
aggregate, the EVs had a significant positive effect (Figure 3.19). Likewise, a generalized linear 
model showed that CTB 100,000 x g EVs increased dESF secretion of the other three factors 
over the 24-h course of the experiment (p<0.001).  
 Next, we asked whether the CTB 100,000 x g EV effects on dESFs were unique. 
Compared to the PBS control, CTB 16,500 x g EVs had a similar effect on dESF secretion of 
the chemokines and cytokines we analyzed. All four factors significantly increased over the 
course of the experiment by a generalized linear model. However, with the exception of 
CXCL1/GRO, the observed increases were smaller in magnitude and for the most part the 
kinetics differed (Figures 3.16-3.19). K562 100,000 x g EVs did not significantly increase 
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secretion of the four factors compared to PBS control treatment at any individual time point, but 
CXCL8/IL-8 secretion was increased over the course of the experiment as determined by the 
generalized linear model. 
Finally, we asked if the addition of rhTNF-a at a concentration comparable to that of CTB 
100,0000 xg EVs could mimic their effects at the protein level. Here, we focused on CXCL8/IL-
8, the dESF chemokine with the most robust response to CTB EVs. The addition of rhTNF-a 
induced dESF secretion of CXCL8/IL-8 in a dose-dependent manner as measured by ELISA 
(Figure 3.20). This increase was much greater than that induced by the CTB 100,000 x g EV 
treatment, possibly because they contain other immunomodulatory contents that may constrain 
the inflammatory and angiogenic response to TNF-a.  
 
TNF-a in cytotrophoblast 100,000 x g extracellular vesicles increases dESF IL-8 secretion 
 Since CTB 100,000 x g EVs contain TNF-a, we tested whether this cytokine is 
necessary for increased dESF secretion of NF-kB targets. Initially, we used neutralizing anti-
TNF-a antibodies, but those experiments were unsuccessful (data not shown). The placenta is 
known to express a variety of Fc receptors, which bind to the Fc region of antibodies (Saji et al., 
1999; Simister et al., 1996). Immunoblotting revealed that CTB 100,000 x g EVs are reactive 
with an antibody against the neonatal Fc receptor (FcRn) at a size consistent with the molecule 
(Figure 3.21)(Simister and Mostov, 1989).  
As an alternative to neutralizing antibodies, we asked whether a soluble form of the 
TNF-a receptor TNFR1 (sTNFR1) could inhibit the effects of CTB 100,000 x g EVs on dESF IL-
8 secretion (Figure 3.22). Because the vesicles were isolated from primary CTBs and their 
quantity was limited, we focused on the 12 h time point. CTB 100,000 x g EV treatment 
increased IL-8 secretion by 2.1-fold compared to PBS (p<0.05), whereas pre-incubating the 
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vesicles with sTNFR1 returned IL-8 secretion to baseline (p<0.005; Figure 3.23). Thus, the 
observed effects of CTB 100,000 x g EVs on dESF IL-8 secretion were attributable to TNF-a.  
 
Discussion 
 Here, we investigate the function of CTB EVs in the uterus. We report the discovery of 
TNF-a in CTB 100,000 x g EVs. These vesicles increased decidual cell transcription and 
secretion of NF-kB target cytokines: CXCL8/IL-8, IL-6, CCL2/MCP-1, and CXCL1/GRO. 
However, not all targets upregulated by CTB-conditioned medium were significantly increased 
by EVs (Hess et al., 2007). rhTNF-a mimicked the ability of EVs to enhance transcription of NF-
kB target genes and secretion of IL-8. A soluble form of the TNF-a receptor inhibited the ability 
of CTB 100,000 x g EVs to increase dESF secretion of IL-8, linking TNF-a with decidual cell 
release of this molecule.  
 TNF-a was only detected in the 100,000 x g pellet, but both EV populations enhanced 
dESF transcription and secretion of NF-kB targets. Two possibilities could explain this 
discrepancy. First, the 16,500 x g pellet was a heterogenous population and many vesicles 
overlapped in size with the 100,000 x g fraction (Figures 2.2 and 2.3). It is possible that TNF-a 
was present in the 16,500 x g pellet at a concentration sufficient to drive NF-kB signaling but too 
low for detection by cytokine array. Second, stimuli other than TNF-a can activate the NF-kB 
pathway (Oeckinghaus and Ghosh, 2009). The 16,500 x g fraction could contain a different NF-
kB activator. Additional experiments using sTNFRI to block TNF-a on 16,500 x g EVs may 
clarify whether the mechanism driving enhanced dESF transcription and secretion of NF-kB 
targets is the same between both EV populations.  
 Soluble TNF-a trimers are unstable at bioactive concentrations (Corti et al., 1992). The 
trimeric form of the cytokine is stable at high concentrations, but at 3.12 ng/ml, half of the 
molecules dissociate into monomers after 72 h (Corti et al., 1992). Packaging this molecule into 
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EVs may stabilize the molecule at low concentrations and allow for delivery with other 
immunomodulatory molecules.  
TNF-a, CXCL8/IL-8, CCL2/MCP1, CXCL1/GRO, and their receptors are present at the 
maternal-fetal interface at early and mid-gestation in humans, bolstering the in vivo relevance of 
this study. Anti-TNF-a staining localizes to first and second trimester invasive and endovascular 
CTBs and decreases to only weak staining in spiral arteries at term (Pijnenborg et al., 1998). In 
situ hybridization revealed that the decidual stroma uniformly expresses CXCL1/Gro-a, while 
CCL2/MCP-1 localizes strongly to isolated patches of these cells and at a lower level (Red-
Horse et al., 2001). In terms of receptors, CTBs immunostain with anti-CXCR1 (CXCL8/IL-8 
receptor) by immunohistochemistry and variably express mRNAs for CXCR2 (CXCL8/IL-8 and 
CXCL1/GRO-a receptor) and CCR2 (CCL2/MCP-1 receptor), indicating that dESF cytokines 
may be part of a network of paracrine signals that can influence CTBs (Drake et al., 2004; 
Hanna et al., 2006). Decidual leukocytes express mRNAs for CCR4 (CCL2/MCP-1 receptor) 
consistently and for CXCR1 and CXCR2 variably (Red-Horse et al., 2001), suggesting a role for 
recruitment of immune cells to the maternal-fetal interface.  
CTB EV-induced dESF cytokine secretion may play important roles in CTB migration 
and recruitment of immune cells to the decidua. IL-8 increases first trimester primary CTB 
migration, whereas MCP-1 has no effect (Hanna et al., 2006). Another study found that IL-6 
secreted by endometrial cells is partially responsible for promoting migration of trophoblast cell 
lines in vitro (Dominguez et al., 2008). MCP-1 is a chemoattractant for monocytes, NK cells, and 
T cells (Allavena et al., 1994; Carr et al., 1994; Matsushima et al., 1989; Valente et al., 1988). 
Thus, the CTB EV-dESF interactions have effects on other types of cells that play important 
roles in pregnancy outcome.  
 Based on studies of the biological activities of CTB-conditioned medium, EVs likely have 
broader functional effects on the uterine environment. CTBs secrete factors that promote 
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lymphangiogenesis via a mechanism that partially depends on TNF-a (Red-Horse et al., 2006). 
First trimester CTB-conditioned medium induces peripheral monocyte differentiation into 
macrophages and alters their ability to secrete cytokines (Aldo et al., 2014). CTB secreted 
factors induce apoptosis of smooth muscle cells in spiral arteries via Fas ligand, a 
transmembrane protein that has been identified on CTB EVs (Abrahams et al., 2004; Harris et 
al., 2006). Thus, although we focused on the function of TNF-a in the context of CTB EVs, we 
believe that this molecule is one of many that can play important roles in modulation of the 
uterine environment, with possible systemic effects. 
In the gray short-tailed opossum, a marsupial whose pregnancy is much shorter than 
eutherian mammals, trophoblast contact with the uterus is correlated with transcription of TNF, 
IL6, CXCL8 (IL-8), and other cytokines, indicating conservation of an inflammatory response at 
implantation across mammalian species (Griffith et al., 2017). However, inhibition of most 
cytokines does not prevent implantation in mice and humans, suggesting redundant pathways. 
Individual genetic deletions of TNF, IL6, CXCL1 (GRO), or CCL2 (MCP-1) result in fertile mice 
with normal litter sizes (Boisvert et al., 2006; Lu et al., 1998; Marino et al., 1997; Pasparakis et 
al., 1996; Robertson et al., 2010). However, suppression of uterine NF-kB activity with an 
inhibitory subunit of the complex delays implantation by one day in mice (Nakamura et al., 
2004). TNF-a and IL-6 inhibitors are prescribed to treat human autoimmune disease, and 
women on these biologic therapies have live births. However, even transient treatment with 
TNF-a inhibitors during pregnancy may increase the risk of birth defects and preterm labor, but 
it is difficult to separate TNF-a effects and those of the underlying maternal disease (Johansen 
et al., 2018). Data on IL-6 inhibition during pregnancy is more limited and drawn from smaller 
sample sizes. Results to date suggest an increased risk of preterm birth but not fetal anomalies 
(Hoeltzenbein et al., 2016). Overall, these findings suggest redundant mechanisms; 
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simultaneous blockade of multiple cytokines may be required to negatively impact implantation 
and maintenance of pregnancy. 
In addition to implantation, parturition is associated with an inflammatory response 
across species. Genetic deletion of IL6 in mice results in a 24 h delay in delivery, which is 
restored to normal with administration of recombinant IL-6 (Robertson et al., 2010). In humans, 
CXCL8/IL-8 is upregulated at parturition in the myometrium and the decidua, where it localizes 
to the stroma and may have a role in cervical dilation (Osmers et al., 1995; Sakamoto et al., 
2004). Microarray analyses showed that labor increases term decidual expression of TNFAIP3, 
IL6, NFKBIA, and other NF-kB targets (Rinaldi et al., 2017). Additionally, labor increases 
decidual expression of CXCL8 while decreasing that of CCL2 (El-Azzamy et al., 2017). Thus, 
the ability of CTB EVs to modulate the expression of NF-kB targets across gestation could have 
important effects at many stages of pregnancy. 
Pregnancy requires a balance between inflammatory and tolerizing mechanisms. How 
do TNF-a-containing CTB EVs avoid immune activation and pregnancy rejection? The NF-kB 
complex regulates hundreds of genes and it is unlikely that pregnancy affects every target 
(Cookson and Chapman, 2010). In mice, epigenetic silencing inhibits decidual stromal cell 
production of inflammatory chemokines CXCL9, CXCL10, and CCL5, thus preventing T cell 
accumulation in the uterus (Nancy et al., 2012). A similar mechanism likely exists in humans 
that constrains the NF-kB response, but allows for the production of specific TNF-a-induced 
cytokines and chemokines. 
Preeclampsia increases circulating levels of placental EVs (Germain et al., 2007; Knight 
et al., 1998; Lok et al., 2008). Perfusion-derived STB EVs from preeclamptic and normal 
placentas differ in contents and function. For example, in preeclampsia, STB EVs contain 
increased levels of Flt-1 and the percentage of endoglin-containing vesicles decreases 
(Tannetta et al., 2013). These anti-angiogenic molecules may contribute to the perturbation of 
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maternal vasculature responses that is the hallmark of this pregnancy complication (Tannetta et 
al., 2013). These EVs also contain reduced levels of endothelial nitric oxide synthase and nitric 
oxide (Motta-Mejia et al., 2017). Additionally, STB EVs have an increased ability to activate 
platelets (Tannetta et al., 2015). Overall, it is unclear whether vesicles contribute to the 
pathology of the disease or are due to compensation by the placenta.  
 In this work, we identified CTB EV function in the uterus. Since CTBs are in direct 
contact with maternal blood, they likely secrete EVs into circulation to mediate pregnancy-
associated changes throughout the mother’s body. For example, many organs enlarge during 
pregnancy. Blood volume expands by almost 50% (Hytten, 1985). The liver increases in size to 
meet the enhanced demands of the embryo/fetus (Hollister et al., 1987). In mice, pregnancy 
stimulates neurogenesis in the maternal olfactory bulb via a prolactin-mediated mechanism 
(Medina and Workman, 2018; Shingo et al., 2003). Pregnant women develop insulin resistance, 
increasing glucose availability for the growing embryo/fetus and requiring the maternal pancreas 
to secrete higher levels of insulin (Lain and Catalano, 2007). The mechanism underlying 
pancreatic adaptation to pregnancy is unknown. Thus, placental EVs may play a role in a subset 
of these maternal responses to pregnancy. Additional studies will focus on a role for CTB EVs in 
mediating distant physiological changes required for reproductive success.   
 
Materials & Methods 
Placental tissue, CTB isolation and culture, and EV preparation 
Tissue was collected, CTBs were isolated, and EVs were prepared as described in the Materials 
& Methods section of Chapter 2.  
K562 cell culture 
 Erythroleukemic K562 cell cultures were seeded with 1x105 cells per ml Iscove's 
Modified Dulbecco's Medium modified with 10% fetal bovine serum (FBS) and 1% penicillin and 
streptomycin. They were grown in 15 cm dishes at 37°C in 5% CO2/95% air. For EV isolation, 
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K562 cells were pelleted at 400 x g and resuspended (1x105 cells/ml) in AIM-V serum-free 
medium (Gibco).  
Profiling EV cytokines 
To identify cytokine contents, 2 µg of EV protein was diluted to 1 ml with ESF medium 
containing 2% charcoal-stripped FBS, DMEM, insulin 0.5%, and MCDB 105 medium (Sigma-
Aldrich). The samples were profiled with the MILLIPLEX MAP Human High Sensitivity T Cell 
Panel (Millipore, #HSTCMAG-28SK) on a Luminex LX 200 analyzer (Luminex) using Bio-Plex 
manager software 6.1.1 (Bio-Rad). 
Immunoblotting and immunofluorescence 
EVs or cell lysates were lysed as described in Chapter 2. For FcRn immunoblotting, 10 
µg protein was solubilized in NuPAGE LDS Sample Buffer containing 0.1 M dithiothreitol (DTT). 
For TNF-a immunoblots, 10 ug protein was concentrated to near dryness with a CentriVap 
(LabConco) and reconstituted with 8 M urea buffer (pH 5.9). 1M DTT and 4x NuPAGE LDS 
Sample Buffer were added to final concentrations of 0.1 M and 1x, respectively. Samples were 
boiled for 10 min, separated on a NuPAGE 4-12% Bis-Tris gel (Invitrogen), and transferred to a 
0.45 µm nitrocellulose membrane (Bio-Rad). Blocking was accomplished with 5% powdered 
nonfat dry milk reconstituted in PBS-T (0.1% Tween in phosphate buffered saline). Membranes 
were incubated in primary antibody diluted in blocking buffer at 4°C overnight. The isotype, 
dilution, and source for each of the primary and secondary antibodies is summarized in Table 
3.1. Immunoreactive bands were visualized with ECL2 Western blotting substrate (Thermo 
Scientific Pierce) and Amersham Hyperfilm ECL (GE Healthcare). 
Immunofluorescence was performed as previously described (Robinson et al., 2017). 
Briefly, tissue was fixed in 4% paraformaldehyde and dehydrated by passing through sequential 
solutions containing increasing sucrose concentrations before embedding in OCT (Thermo 
Fisher Scientific). Sections (15 µm) were incubated with rat anti-human cytokeratin 7 (Damsky 
et al., 1992) to label CTBs and mouse anti-human TNF-a diluted at 1:100 (vol/vol) in blocking 
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buffer (PBS with 3% bovine serum albumin) for 1 h at room temperature. Primary antibodies 
were detected with species-specific secondary antibodies; details on these antibodies and their 
sources are described in Table 3.2.  Sections were washed in PBS and mounted with 
Vectashield containing 4′6-diamidino-2-phenylindole (Vector Bio-Laboratories). Samples were 
visualized with a Leica SP5 confocal microscope or a Leica DM5000 B inverted microscope. 
Tissue sections from 3 placentas were evaluated. 
Endometrial stromal fibroblast culture and decidualization 
 Human endometrial samples were collected from the UCSF/NIH Human Endometrial 
Tissue and DNA Bank after written informed consent. Endometrial stromal fibroblasts (ESFs) 
were isolated from endometrial biopsies (n=20). They were washed in PBS and digested with 
collagenase IV for 1 h at 37ºC with constant shaking. The digests were size fractionated by 
passing through a 40 µm filter. The primary cells present in the filtrate and subsequent 
passages were cultured in stromal cell medium (SCM): 10% charcoal-stripped fetal bovine 
serum-containing medium, DMEM, 1 mM sodium pyruvate, 5 µg/ml final concentration insulin, 
and MCDB 105 (Irwin et al., 1989). Only morphologically homogenous ESF cell cultures as 
determined by microscopic examination were used in experiments. Prior to decidualization, 
cultured ESFs were serum-starved for 24 h in 2% charcoal-stripped fetal bovine serum-
containing medium without insulin. Then they were treated with 10 nM E2 and 1 µM P4 in ESF 
medium (E2P4 medium) or the vehicle control for 14-21 days (Houshdaran et al., 2014). 
Decidualization was assessed by using an ELISA to quantify IGFBP1 secretion into the medium 
(Alpha Diagnostic International Inc., #0900) and by assessing microscopic examination to 
assess morphologic changes. The 3 ESF cell lines exhibiting the most robust decidualization 
were used in the initial screens. The subsequent functional assays also employed the same 3 
ESF lines, which were frozen, thawed, and decidualized for each set of experiments.  
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EV effects on the ESF secretome and the role of TNF-a 
The effects of EVs from 3 CTB cultures established from different placentas were 
analyzed. A portion of each EV fraction that was aliquoted in PBS was added to the hormone-
containing ESF medium to a final concentration of 2 µg per ml. Typically, 10 ml batches were 
prepared. A portion (500 µl) was reserved as a control for downstream analyses and 1 ml was 
added to each decidualized ESF (dESF) well. The cells were cultured for 3, 12, or 24 h, at which 
point conditioned medium was collected and centrifuged at 400 x g. The supernatant was stored 
at -80ºC. The cells were washed with PBS, detached from the plate by treatment with 0.25% 
trypsin with EDTA in PBS (Ca++/Mg++-free), and pelleted by centrifugation at 400 x g. The pellets 
were flash frozen in a dry ice-ethanol slush and stored (-80ºC).  
Samples of dESF RNA were prepared for analysis by a chip-based method of qRT-PCR 
using a 96.96 Dynamic Array integrated fluidic circuit (IFC; Fluidigm) according to the 
manufacturer’s protocol. Total RNA was isolated from frozen cell pellets with a NucleoSpin RNA 
isolation kit (Machery-Nagel). The concentration and quality were estimated using a Nanodrop 
spectrophotometer (Thermo Fisher Scientific). cDNA libraries were prepared with 150 ng RNA 
using Reverse Transcription Master Mix (Fluidigm) and pre-amplified with Preamp Master Mix 
(Fluidigm) and pooled delta gene assay mix (500 nm; Fluidigm). The samples were digested 
with exonuclease I (New England BioLabs), and diluted 1:10 (vol/vol) in 1x DNA suspension 
buffer (TEKnova). Delta gene assay primer sequences are listed in Table 3.3. Samples were 
prepared with 2x SsoFast EvaGreen Supermix with low ROX (Bio-Rad) and 20x DNA Binding 
Dye (Fluidigm). Primer mixes contained 2x Assay Loading Reagent (Fluidigm), 1x DNA 
Suspension Buffer, and Delta gene assay combined forward and reverse primers (100 µM). 
After priming and loading the 96.96 chip using an IFC Controller HX (Fluidigm), qRT-PCR data 
were collected on a Biomark instrument (Fluidigm). Statistics were performed on dCt values 
calculated as the difference in Ct values between the gene of interest and the average of two 
housekeeping genes: HSP90AB1 and G6PD. Differential expression between EV treatments 
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and controls was calculated via the ΔΔCT method: normalized to the mean of housekeeping 
genes and adjusted to the PBS control for each ESF line, EV batch, and time point. 
We measured changes in dESF NF-kB target secretion in response to EV treatment 
using a custom MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel (Millipore, # 
HCYTOMAG-60K) to assay conditioned medium for IL-8 (CXCL8), IL-6, MCP-1 (CCL2), and 
GRO. These experiments employed a Luminex LX 200 analyzer (Luminex) and the data were 
generated by using Bio-Plex manager software 6.1.1 (Bio-Rad).  
To determine the effects of recombinant human TNF-a (rhTNF-a), the lyophilized, E. 
coli-derived protein (R&D Systems, #210-TA) was reconstituted in PBS to a concentration of 0.1 
mg/ml. This working solution was serially diluted to a final concentration of 1 pg/ml, 10 pg/ml, or 
100 pg/ml in E2P4 medium. rhTNF-a-containing medium (1 ml) was added to each well of 
dESFs. As a control, some wells contained E2P4 medium alone. Conditioned medium and cell 
pellets for RNA isolation were collected after 3, 12, or 24 h of culture as described above. 
IL-8 levels were measured with a Quantikine ELISA Kit (R&D Systems, #S8000C) 
according to manufacturer’s instructions. Samples were diluted 1:20 in calibrator diluent RD5P. 
According to the manufacturer’s instruction, a face mask was worn during the assay to prevent 
IL-8 contamination from saliva. 
For TNF-a inhibition experiments, sTNFR1 (R&D Biosystems, #636-R1-025) was 
reconstituted in PBS. EVs diluted in E2P4 medium as described above were incubated with or 
without sTNFR1 (1 µg/ml) for 20 min at 37ºC. An aliquot (1 ml) was added to each dESF well. 
After 12 h, conditioned medium was collected as described above. 
Statistics 
Statistical analyses were performed using SPSs version 24 (IBM). The high sensitivity T 
cell cytokine array and mRNA data were analyzed using a one-way ANOVA with Bonferroni 
correction. The ESF cytokine array data at individual time points and the IL-8 ELISAs were 
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analyzed using a one-way ANOVA with Dunnett’s test. We also generated a generalized linear 
model of cytokine secretion for the time course experiment with time, cell line, EV batch, and 
treatment as independent variables.   
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Figure 3.1 CTB EVs lacked detectable levels of most analytes measured by cytokine 
array. 
EVs (2 µg) were analyzed by a high sensitivity cytokine array. Most analytes were below the 
threshold of detection. In the CTB 100,000 x g pellet, IL-6 was present at ~0.2 pg/µg and MIP-3a 
was detected at ~1 pg/µg. n=3 biological replicates. * p<0.05, **** p<0.001.  
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Figure 3.2 CTB 100,000 x g EVs contained TNF-a. 
As measured by a high sensitivity cytokine array, CTB 100,000 x g EVs contained ~5 pg TNF-a 
per 1 µg total protein (10 pg per 2 µg protein). n=3 biological replicates. **** p<0.001. 
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Figure 3.3 CTB EVs immunoblotted for anti-TNF-a at a size consistent with the trimeric 
membrane form. 
Immunoblotting for TNF-a was used to compare CTB lysate, 16,500 x g EVs, and 100,000 x g 
EVs. The 100,000 x g fraction was immunoreactive for a faint band at ~70kDa, consistent in size 
with the trimeric membrane form of the cytokine. n=2. 
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Figure 3.4 Cytokeratin-positive CTBs express TNF-a in situ. 
Sections of basal plate were stained for CTB-marker cytokeratin (CK, red), TNF-a (green), and 
DAPI (blue), followed by imaging at 20x (left panel, scale=200 µm) and 63x (right panel, scale=10 
µm). TNF-a was present in cytokeratin-positive CTBs in a vesicular pattern. n=3 biological 
replicates.  
 
AV, anchoring villi; CC, cell column; Ut, uterus.  
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Figure 3.5 Schematic of functional assay of CTB EVs on decidualized endometrial 
stromal fibroblasts (dESFs). 
Three sets of human primary dESFs were treated with three batches of CTB 16,500 x g EVs, CTB 
100,000 x g EVs, K562 100,000 x g EVs or PBS. EVs were added to dESF medium to a final 
concentration of 2 µg/mL and 1 mL was added to each well. The cells were cultured 3, 12, or 24 
h, at which point conditioned medium was collected for a cytokine array and cell pellets were 
harvested for RNA analysis. 
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Figure 3.6 CTB EVs increased dESF transcription of NF-kB targets. 
Heat maps of gene expression changes in dESFs as measured by a Fluidigm 96.96 Dynamic 
Array (left) and p-values compared to the PBS control (right). CTB EVs transiently increased 
transcription of NF-kB target genes at 3 h. n=3 biological replicates (each point is the result of a 
matrix of 3 dESF lines treated with 3 EV batches), each EV batch was performed as an 
independent experiment. 
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Figure 3.7 CTB EVs increased dESF transcription of NF-kB target CXCL8. 
Both CTB EV populations increased dESF transcription of CXCL8 (IL-8) at 3 h compared to both 
PBS and K562 100,000 x g EVs as measured by a Fluidigm 96.96 Dynamic Array IFC. There 
were no significant differences at 12 or 24 h. n=3 biological replicates (each point is the result of 
a matrix of 3 dESF lines treated with 3 EV batches), each EV batch was performed as an 
independent experiment. *** p<0.005, **** p<0.001. 
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Figure 3.8 CTB 100,000 x g EVs increased dESF transcription of NF-kB target IL6. 
Compared to PBS control, CTB 100,000 x g EVs increased dESF transcription of IL6 at 3 h. CTB 
16,500 x g EVs increased expression of this RNA at 24 h as measured by a Fluidigm 96.96 
Dynamic Array IFC. n=3 biological replicates (each point is the result of a matrix of 3 dESF lines 
treated with 3 EV batches), each EV batch was performed as an independent experiment. * 
p<0.05, ** p<0.01. 
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Figure 3.9 CTB EVs increased dESF transcription of NF-kB target CXCL1. 
Both CTB EV fractions increased dESF transcription of CXCL1 (GRO) at 3 h compared to the 
PBS and K562 100,000 x g controls as measured by a Fluidigm 96.96 Dynamic Array IFC. n=3 
biological replicates (each point is the result of a matrix of 3 dESF lines treated with 3 EV batches), 
each EV batch was performed as an independent experiment. * p<0.05, *** p<0.005. 
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Figure 3.10 CTB EVs increased dESF transcription of NF-kB target CCL2. 
CTB 100,000 x g EVs increased dESF transcription of CCL2 (MCP-1) at 3h compared to the PBS 
and K562 100,000 x g controls as measured by a Fluidigm 96.96 Dynamic Array IFC. CTB 16,500 
x g EVs also increased expression of this gene compared to PBS at 3h. n=3 biological replicates 
(each point is the result of a matrix of 3 dESF lines treated with 3 EV batches), each EV batch 
was performed as an independent experiment. * p<0.05, ** p<0.01, *** p<0.005. 
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Figure 3.11 Recombinant human TNF-a (rhTNF-a) sustained increased dESF expression 
of NF-kB targets for the duration of the 24 h time course. 
Heat maps of gene expression changes measured by Fluidigm 96.96 Dynamic Array IFC (left) 
and p-values (right) compared to PBS control. Treatment with rhTNF-a increased transcription of 
NF-kB targets that was sustained over the course of the experiment. n=3 biological replicates 
(dESFs), 2 independent experiments. 
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Figure 3.12 rhTNF-a increased dESF transcription of NF-kB target CXCL8 over 24 h. 
Compared to the PBS control, both concentrations of rhTNF-a (1 pg/ml and 10 pg/ml) increased 
transcription of CXCL8 (IL-8) at each time point studied as measured by a Fluidigm 96.96 
Dynamic Array IFC. n=3 biological replicates (dESFs), 2 independent experiments. ** p<0.01, *** 
p<0.005, **** p<0.001. 
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Figure 3.13 rhTNF-a increased dESF transcription of NF-kB target IL6 over 24 h. 
Both concentrations of rhTNF-a (1 pg/ml and 10 pg/ml) increased transcription of IL6 compared 
to the PBS control. Changes in gene expression were measured with a Fluidigm 96.96 Dynamic 
Array IFC. n=3 biological replicates (dESFs), 2 independent experiments. * p<0.05, *** p<0.005, 
**** p<0.001. 
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Figure 3.14 rhTNF-a increased dESF transcription of NF-kB target CXCL1 over 24 h. 
Compared to the PBS control, both concentrations of rhTNF-a (1 pg/ml and 10 pg/ml) increased 
RNA expression of CXCL1 (GRO) at each time point studied as measured with a Fluidigm 96.96 
Dynamic Array IFC. n=3 biological replicates (dESFs), 2 independent experiments. ** p<0.01, *** 
p<0.005, **** p<0.001. 
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Figure 3.15 rhTNF-a increased dESF transcription of NF-kB target CCL2 over 24 h. 
Both concentrations of rhTNF-a (1 pg/ml and 10 pg/ml) increased transcription of CCL2 (MCP-1) 
compared to the PBS control at each time point analyzed with a Fluidigm 96.96 Dynamic Array 
IFC. n=3 biological replicates (dESFs), 2 independent experiments. *** p<0.005. 
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Figure 3.16 CTB 100,000 x g EVs increased secretion of NF-kB target CXCL8/IL-8. 
Conditioned medium from primary dESF lines treated with CTB 100,000 x g EVs, CTB 16,500 x 
g EVs, K562 100,000 x g EVs, or PBS collected at 0, 3, 12, and 24 h was analyzed by cytokine 
array. CTB 100,000 x g EVs significantly increased dESF CXCL8/IL-8 secretion at 3 and 12 h and 
overall compared to the PBS control. CTB 16,500 x g vesicles significantly increased this cytokine 
at 3 h. n=3 biological replicates (each point is the result of a matrix of 3 dESF lines treated with 3 
EV batches), EV batches were performed as independent experiments. ** p<0.01, *** p<0.005, 
**** p<0.001. 
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Figure 3.17 CTB 100,000 x g EVs increased secretion of NF-kB target CXCL1/GRO. 
Conditioned medium from primary dESF lines treated with CTB 100,000 x g EVs, CTB 16,500 x 
g EVs, K562 100,000 x g EVs, or PBS collected at 0, 3, 12, and 24 h was analyzed by cytokine 
array. CTB 100,000 x g EVs significantly increased dESF secretion of CXCL1/GRO at 3h 
compared to the PBS and K562 100,000 x g controls. n=3 biological replicates (each point is the 
result of a matrix of 3 dESF lines treated with 3 EV batches), EV batches were performed as 
independent experiments. * p<0.05. 
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Figure 3.18 CTB 100,000 x g EVs increased secretion of NF-kB target CCL2/MCP-1. 
Conditioned medium from primary dESF lines treated with CTB 100,000 x g EVs, CTB 16,500 x 
g EVs, K562 100,000 x g EVs, or PBS collected at 0, 3, 12, and 24 h was analyzed by cytokine 
array. CTB 100,000 x g EVs enhanced dESF release of CCL2/MCP-1 at 12 h compared to the 
PBS K562 100,000 x g controls. n=3 biological replicates (each point is the result of a matrix of 3 
dESF lines treated with 3 EV batches), EV batches were performed as independent experiments. 
* p<0.05, ** p<0.01. 
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Figure 3.19 CTB 100,000 x g EVs increased secretion of NF-kB target IL-6. 
Conditioned medium from primary dESF lines treated with CTB 100,000 x g EVs, CTB 16,500 x 
g EVs, K562 100,000 x g EVs, or PBS collected at 0, 3, 12, and 24 h was analyzed by cytokine 
array. IL-6 levels were not significantly different at any individual time point. n=3 biological 
replicates (each point is the result of a matrix of 3 dESF lines treated with 3 EV batches), EV 
batches were performed as independent experiments.  
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Figure 3.20 rhTNF-a recapitulated increased dESF CXCL8/IL-8 secretion. 
rhTNF-a treatment induced dESF secretion of IL-8 in a dose-dependent manner as measured by 
ELISA. One pg/ml rhTNF-a treatment increased IL-8 secretion by 4.5-fold at 3 h, 17.4-fold at 12 
h, and 10.9-fold at 24 h. Ten pg/ml rhTNF-a treatment increased IL-8 secretion by 5.7-fold at 3 h, 
26.4-fold at 12 h, and 20.7-fold at 24 h. n=3 biological replicates (dESFs), performed as 2 
independent experiments. * p<0.05, ** p<0.01, *** p<0.005, **** p<0.001. 
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Figure 3.21 CTBs and 100,000 x g EVs contained the neonatal Fc receptor (FcRn). 
Immunoblotting methods revealed that CTB lysate and 100,000 x g EVs were reactive with anti-
FcRn at ~45 kDa, a size consistent with the molecule. n=1.  
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Figure 3.22 Schematic of TNF-a inhibition on EVs and dESF secretion of IL-8. 
CTB 100,000 x g EVs were pre-incubated with a soluble form of the TNF-a receptor (sTNFRI) for 
20 m at 37°C before addition to dESFs. After 12 h culture, conditioned medium was collected and 
analyzed by an ELISA for IL-8. 
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Figure 3.23 TNF-a inhibition attenuated increased dESF IL-8 secretion induced by CTB 
100,000 x g EVs. 
sTNFRI pre-treatment of CTB 100,000 x g EVs returned dESF IL-8 secretion to baseline after 12 
h of culture as measured by ELISA. n=3 biological replicates (each point is the result of a matrix 
of 3 dESF lines treated with 3 EV batches), performed as 1 experiment. * p<0.05, ** p<0.005  
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Figure 3.24 Proposed model of CTB communication with dESFs via EVs. 
CTBs released 100,000 x g EVs containing TNF-a, which increased dESF transcription and 
secretion of NF-kB targets. 
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Table 3.1 Antibodies for immunoblotting 
Primary Antibodies Secondary Antibodies 
Target Clone Supplier Catalog # Host Dilution Antibody Conjugate Supplier Dilution 
FcRn Polyclonal 
Laboratory of 
N.E. Simister N/A mouse 1:200 
Donkey 
anti-
mouse Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
TNF-a 2C8 Abcam ab8348 mouse 1:500 
Donkey 
anti-
mouse Peroxidase 
Jackson 
ImmunoResearch 
Labs, Inc. 1:5000 
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Table 3.2 Antibodies for immunofluorescence 
Primary Antibodies Secondary Antibodies 
Target Clone Supplier Catalog # Host Dilution Antibody Conjugate Supplier Dilution 
CK 7D3 
Laboratory of 
S.J. Fisher N/A rat 1:100 
Donkey 
anti-rat Rhodamine 
Jackson 
ImmunoResearch 
Labs, Inc. 1:100 
TNF-a 2C8 Abcam ab8348 mouse 1:100 
Donkey 
anti-
mouse  FITC 
Jackson 
ImmunoResearch 
Labs, Inc. 1:100 
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Table 3.3 qRT-PCR primers 
 
  
Target Forward Primer Reverse Primer 
ACTA2 AAGGCCAACCGGGAGAAAA CGCCTGGATAGCCACATACA 
ANGPT1 TCCAAAGAGGCTGGAAGGAA CCTCTGACTGGTAATGGCAAAA 
ANGPTL4 TCCACTTGGGACCAGGATCA AATGGCTGCAGGTGCCAAA 
APOE CCCAGGTCACCCAGGAAC TGTTCCTCCAGTTCCGATTTGTA 
BMP2 ACTGTGCGCAGCTTCCA ACTCCTCCGTGGGGATAGAA 
CCL2 TAGCAGCCACCTTCATTCCC CCTCTGCACTGAGATCTTCCTA 
CCND3 CGACAGGCCTTGGTCAAAA ATCATGGATGGCGGGTACA 
CSF1 GGAGACCTCGTGCCAAATTA TGCCTTCTTAAGGTAGCACAC 
CXCL1 CTTGCCTCAATCCTGCATCC AGCCACCAGTGAGCTTCC 
CXCL12 GCTGGTCCTCGTGCTGAC GAATCGGCATGGGCATCTGTA 
CXCL8 ACACTGCGCCAACACAGAAA CAGTTTTCCTTGGGGTCCAGAC 
EGFR AGTGTAAGAAGTGCGAAGGG TCGTAGCATTTATGGAGAGTGAG 
FGF1 TCTGCCTCCAGGGAATTACA CCTGTCCCTTGTCCCATCC 
FN1 GTGTGTGTGTCTTGGTAATGGAAA AGTCCCAGCAGCATGATCAA 
FOSL1 ATTGAGGAGCTGCAGAAGCA CCCTCCTTGGCTCCTTCC 
FZD1 GCTTCGTGGGGCTTAACAAC ACGTGCCGATAAACAGGTACA 
FZD2 CCTTCTTCACTGTCACCACGTA TGTAGCAGCCCGACAGAAAA 
FZD7 TCCGCACCATCATGAAACAC GTGTAGAGCACGCTGAAGAC 
G6PD GCCGTCACCAAGAACATTCA CTCCCGAAGGGCTTCTCC 
HSP90AB1 TCCTTCGGGAGTTGATCTCTA GGGTCTGTCAGGCTCTCATA 
ICAM1 CCCCTACCAGCTCCAGACC TGCGTGTCCACCTCTAGGAC 
IFIT1 AGGCTGTCCGCTTAAATCCA TCAGCTTCCTGTCCTTCATCC 
IL6 AGAGCTGTGCAGATGAGTACAA GTTGGGTCAGGGGTGGTTA 
IL7 ATTGAAGGTAAAGATGGCAAACA TCATTATTCAGGCAATTGCTACC 
IRAK2 GTCTGGAGATCATCCACAGCAA TGAGCCATTGGGTGAGCAA 
JUN AAGAACTCGGACCTCCTCAC TGGATTATCAGGCGCTCCA 
JUNB TGGCCCAGCTCAAACAGAA AGAAGGCGTGTCCCTTGAC 
KDR AGTGGGCTGATGACCAAGAA CCATGCCACTTCCAAAAGCA 
LIF CTCGGGTAAGGATGTCTTCCA ACACGGCGATGATCTGCTTA 
MMP1 CACCTTCAGTGGTGATGTTCA GCTGGACAGGATTTTGGGAA 
MMP10 TGAGCCTAAGGTTGATGCTGTA GGCATTGGGGTCAAACTCAA 
MMP7 TGTATGGGGAACTGCTGACA ATGAGCCAGCGTGTTTCC 
NFKB1 CTACCTGGTGCCTCTAGTGAAA ACCTTTGCTGGTCCCACATA 
NFKB2 TACCTGGTGATCGTGGAACA GCCTTCACAGCCATATCGAA 
OLFM2 GGCTCCTGGATGACTGACA GGCGGCCTTTGTAATAGCC 
RELA GCATCCAGACCAACAACAACC AGAGCCGCACAGCATTCA 
RELB TGCTTTCCGAGCCCGTCTA CGGCCCGCTTTCCTTGTTAA 
TNFAIP2 AAGAGCCACGGCTTTGACA GTGTGCGTGAACCTCTTGAAC 
TNFAIP3 GAAGCTTGTGGCGCTGAAAA CCTGAACGCCCCACATGTA 
WNT5B ATTGCAGCACAGCGGACAA CTCACCGCGTGGGTGAA 
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The pancreas, b-cells, and insulin production 
 The pancreas regulates metabolism and is made up of two parts with distinct functions: 
exocrine and endocrine (Zhou and Melton, 2018). Exocrine acinar cells produce digestive 
enzymes, which are secreted into the pancreatic ducts for release into the small intestine 
(Roder et al., 2016). The endocrine component of the pancreas is organized into islets 
containing 5 cell types: insulin-producing b-cells, glucagon-producing a-cells, somatostatin-
producing d-cells, pancreatic polypeptide-producing (PP) cells, and ghrelin-producing e-cells 
(Zhou and Melton, 2018). 
 b-cells and a-cells exert opposing functions to maintain normoglycemia. In response to 
high blood glucose, b-cells secrete insulin, which signals for muscle and adipose tissue to take 
up excess glucose, returning circulating concentrations to normal (Roder et al., 2016). When 
blood glucose levels drop, a-cells release glucagon, which stimulates liver gluconeogenesis, 
restoring homeostasis (Goke, 2008). Pancreatic islet dysfunction disrupts the balance between 
b-cells and a-cells, resulting in metabolic disease. For example, insufficient insulin and excess 
glucagon is a hallmark of type 2 diabetes mellitus and gestational diabetes mellitus (Beis et al., 
2005; Goke, 2008). 
 
Placental lactogen mediates rodent b-cell adaptation to pregnancy 
 In human pregnancy, maternal organs become insulin resistant to promote glucose 
uptake by the feto-placental unit (Lain and Catalano, 2007). To meet demand for increased 
insulin secretion, the pancreas increases in size, and b-cells increase in number (Butler et al., 
2010; Van Assche et al., 1978). The mechanisms underlying these changes are unknown. It is 
unclear whether cell numbers increase by b-cell proliferation or by another population 
transdifferentiating into insulin-producing cells.  
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 The mechanisms behind maternal pancreatic adaptation to pregnancy have been 
defined in rodent models. In rat pregnancy, cells in pancreatic islets proliferate and are labelled 
with BrdU beginning at day 10 of pregnancy and peaking at day 14 (Figure 4.1, left panel) 
(Parsons et al., 1992). This event coincides with the detection of placental lactogen in maternal 
circulation starting at day 10 and with bimodal peaks at days 12 and 18 (Figure 4.1, left panel) 
(Parsons et al., 1992). Although both b-cell proliferation and lactogen secretion begin at day 10, 
overall activities of the two are not parallel. This may reflect the fact that lactogen comprises the 
initial signal required for proliferation after which other messengers from the placenta and 
elsewhere may be required to sustain this process.  
 In addition to increasing b-cell number, pregnancy also enhances insulin secretion. 
Pancreatic islets isolated from pregnant mice (gestational day 13) release more insulin in 
response increasing glucose concentrations compared to those from non-pregnant controls 
(Figure 4.2) (Ohara-Imaizumi et al., 2013). The difference between the two groups increases at 
higher levels of glucose, perhaps plateauing between 20 and 25 mM.  
 The mechanism underlying mouse pancreatic adaptation to pregnancy is well defined 
(Figure 4.3). The placenta releases placental lactogen into the maternal circulation (Welsch, 
1979). The hormone binds to the prolactin receptor (PRLR) on b-cells, resulting in the 
transcription of tryptophan hydroxylase (TPH), which increases serotonin (5HT) synthesis from 
tryptophan (Trp) (Kim et al., 2010). This neurotransmitter is secreted into the extracellular 
space, where it acts in an autocrine/paracrine manner and binds to its receptors HTR2B and 
HTR3A on b-cells (Kim et al., 2010; Ohara-Imaizumi et al., 2013). HTR2B promotes cell cycle 
progression and proliferation, while the sodium ion channel HTR3A increases insulin secretion 
(Kim et al., 2010; Ohara-Imaizumi et al., 2013). Towards the end of pregnancy, expression of 
HTR2B returns to normal levels, while expression of the inhibitory receptor HTR1D increases, 
decreasing proliferation (Kim 2010). 
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Mechanisms of pancreatic adaptation to pregnancy differ between human and mouse 
 Adult human b-cells are resistant to proliferation (Wang et al., 2015). Mouse b-cell 
mitogens do not promote a similar response in human cells (Baeyens et al., 2018). For 
example, placental lactogen does not stimulate replication in human islets as measured by EdU 
incorporation (Figure 4.4).  
 To determine whether murine pregnancy can drive human b-cell proliferation, adult 
human islets were transplanted beneath the mouse kidney capsule (Figure 4.5 A). After allowing 
for engraftment, a portion of the mice were impregnated. Concentrations of human C-peptide, a 
byproduct of insulin production, did not differ between non-pregnant and pregnant mice (Figure 
4.5 B). In both groups, human b-cells did not proliferate as determined by EdU incorporation 
(Figure 4.5 C). In contrast, mouse b-cells in the pregnant mice replicated, and 10% were 
positive for EdU (Figure 4.5 D). Therefore, mechanisms underlying pancreatic adaptation to 
pregnancy are species-specific. 
 
Human cytotrophoblast 100,000 x g extracellular vesicles promote b-cell proliferation and 
insulin secretion 
 Because the placenta mediates pancreatic adaptation to pregnancy in mice, we 
investigated whether human placental cytotrophoblasts (CTBs) and their extracellular vesicles 
(EVs) promote b-cell proliferation and insulin secretion. Mice transplanted with human 
pancreatic islets underwent one of two treatments: CTBs were transplanted under the other 
kidney capsule or CTB 100,000 x g EVs were injected into the tail vein (Figure 4.6). Both 
treatments dramatically increased human b-cell proliferation as measured by EdU incorporation 
(Figure 4.7). Only mouse pregnancy enhanced mouse b-cell proliferation, reinforcing the 
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overarching principal that the mechanisms of pancreatic adaptation to pregnancy are different in 
mice and humans.  
 We asked whether this mitogenic activity was specific to the 100,000 x g EV population 
or a general property of CTB EVs. In these experiments, either CTB 16,500 x g EVs or 100,000 
x g EVs were injected into the tail veins of mice transplanted with human islets. Only the 
100,000 x g fraction increased the transplanted cells’ incorporation of EdU (Figures 4.8 and 
4.9). The proliferating cells retained expression of Nkx6.1, a marker of mature b-cells, and 
continued to secrete insulin (Figure 4.8). In contrast, CTB 16,500 x g EVs did not stimulate EdU 
incorporation. Additionally, the mitogenic activity, which was restricted to the 100,000 x g 
fraction, was sustained over the course of the experiment, which lasted for 64 days (Figure 4.9). 
Together, these experiments indicate that the 100,000 x g EVs had the unusual property of 
inducing b-cell proliferation without loss of mature markers or insulin secretion. 
 In additional experiments, we investigated whether the observed effects were cell type-
specific. To this end, we generated HeLa cell 100,000 x g EVs. These vesicles did not stimulate 
b-cell proliferation as measured by EdU incorporation in vivo (Figure 4.7). To test whether other 
HeLa cell EV populations could drive b-cell replication in vitro, we cultured human islets with 
vesicles isolated at 3 different speeds: 2,000 x g, 16,500 x g, and 100,000 x g. HeLa EVs failed 
to increase b-cell proliferation as measured by EdU incorporation (Figure 4.10, upper panel) and 
Ki67 staining (Figure 4.10, lower panel). Together, these data suggest that the ability of 100,000 
x g EVs to drive b-cell proliferation is specific to those derived from CTBs. 
 We addressed whether human placental lactogen synergizes with CTB 100,000 x g EVs 
to drive b-cell proliferation and insulin production in vitro. Human islets were cultured with 3 
populations of CTB EVs: 2,000 x g, 16,500 x g, and 100,000 x g. Only CTB 100,000 x g EVs 
increased b-cell proliferation as measured by EdU incorporation, and human placental lactogen 
had no additional effects (Figure 4.11, upper panel). In agreement with this result, only CTB 
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100,000 x g EVs increased the number of proliferating Ki67-positive, insulin-producing cells, and 
again placental lactogen had no effect (Figure 4.11, lower panel). The proliferating Ki67-positive 
cells retained insulin secretion, suggesting that mature b-cells replicate without dedifferentiation. 
Furthermore, only the CTB 100,000 x g EVs increased glucose-stimulated insulin secretion; the 
addition of human placental lactogen further enhanced this activity (Figure 4.12). Thus, CTB 
100,000 x g EVs increased b-cell proliferation and insulin secretion.  
 Because serotonin induces mouse b-cell proliferation, we investigated whether this 
neurotransmitter synergizes with CTB 100,000 x g EVs. Addition of serotonin to pancreatic islets 
did not influence alter CTB EV-induced b-cell proliferation as measured by EdU incorporation 
(Figure 4.13). This reinforces the principle that mechanisms of pancreatic adaptation to 
pregnancy differ between human and mouse.  
 To further investigate the mechanism underlying CTB 100,000 x g EV-induced b-cell 
proliferation, we disrupted the vesicles by sonication prior to adding them to pancreatic islets. 
Sonication abolished proliferative effects of CTB 100,000 x g EVs as measured by EdU 
incorporation (Figure 4.14). Therefore, vesicle structure must be intact to deliver the activator, 
which could be an RNA or protein. Of note, this experiment was performed a single time and 
replicates are needed to reach a firm conclusion. 
 We next compared the in vitro effects of CTB 100,000 x g EVs on human pancreatic 
islets to those of known b-cell mitogens. The vesicles stimulated proliferation of b-cells to a 
greater extent than the drugs and compounds tested (Figure 4.15). Additionally, CTB 100,000 x 
g EVs had no effect on a-cell proliferation. Thus, the vesicles specifically targeted b-cells to 
promote adaptation to pregnancy. 
 To gain insights into possible mechanisms, RNA-seq was performed on pancreatic islets 
treated with CTB 100,000 x g EVs versus a negative control. Gene set enrichment analysis 
(GSEA) revealed that the vesicles upregulated the expression of genes involved in cell cycle 
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progression (Figure 4.16). Thus, these experiments confirmed the results described above in 
terms of vesicle stimulation of pancreatic islet EdU incorporation and Ki67 staining. 
 
Cytotrophoblast 100,000 x g extracellular vesicles promote human embryonic stem cell 
differentiation into b-cells 
 Since CTB 100,000 x g EVs stimulated primary b-cell proliferation without the loss of 
mature markers, we asked whether the vesicles could enhance human embryonic stem cells 
(hESCs) differentiation into this cell type. To this end, we treated b-like cells with CTB EVs 
isolated at 2,000 x g, 16,500 x g, and 100,000 x g. Only CTB 100,000 x g EVs increased the 
percentage of cells positive for C-peptide as measured by flow cytometry (Figure 4.17, left 
panel). In terms of function, glucose-stimulated insulin secretion (GSIS) of hESC-derived b-like 
cells was calculated by dividing insulin secretion at high glucose (20 mM) by response at low 
glucose (2.8 mM). Only CTB 100,000 x g EVs increased glucose responsiveness of b-like cells 
(Figure 4.17, right panel). Thus, these vesicles improved differentiation and function of these 
cells by enhancing their insulin secretion.  
 
Discussion 
 Here, we investigate the role of CTB 100,000 x g EVs at sites beyond the uterus. 
Specifically, we examined their effects in terms of maternal pancreatic adaptation to pregnancy. 
These vesicles stimulated human pancreatic b-cell proliferation and insulin secretion both in 
vivo and in vitro. Proliferating cells maintained expression of the mature b-cell marker Nkx6.1. 
This indicates that increased b-cell number is due to replication of mature cells, rather 
dedifferentiation to a precursor prior to proliferation or transdifferentiation of other cell types into 
b-cells. The effect was specific to both cell type and vesicle type, as HeLa 100,000 x g EVs and 
other CTB EVs isolated at 2,000 x g and 16,500 x g did not increase b-cell proliferation. 
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Furthermore, the mechanisms were distinct from those in mice, as mouse pregnancy had no 
effect on human cells. Placental lactogen synergized with CTB 100,000 x g EVs to promote 
insulin production, but not proliferation. The vesicles stimulated b-cell, but not a-cell, 
proliferation to a greater extent than known mitogens. Finally, CTB 100,000 x g EVs enhanced 
differentiation of hESC-derived b-like cells. Overall, the data suggest that CTBs play an 
important role in pancreatic adaptation to pregnancy through EVs released into the maternal 
circulation. 
 Additional studies are needed to identify the specific cargo within CTB EVs that 
promotes b-cell proliferation and insulin production, as well as hESC differentiation. It could be 
one of many RNA species or proteins identified in CTB EVs by mass spectrometry. RNA-
sequencing of the vesicle contents is challenging due to limited quantities of starting material 
but may become more feasible as methods improve and/or trophoblast cell lines that produce 
these EVs are identified. It may be possible to identify miRNA candidates by analyzing 
sequences of differentially expressed genes. Different bioinformatic approaches to analyze EV-
induced changes in b-cell gene expression could reveal additional insights into mechanisms and 
mediators. 
 It is logical to predict that gestational diabetes mellitus could be the result of defective 
CTB 100,000 x g EV communication with maternal pancreatic b-cells. The problem could lie in 
the vesicle contents or islet responses. This complication does not always recur in second 
pregnancies (Kim et al., 2007), suggesting that defective b-cell proliferation is due to a missing 
feto-placental signal. Future studies comparing the contents and functions of CTB EVs from 
normal versus gestational diabetic pregnancies could uncover the root causes of this pregnancy 
complication.  
 CTB 100,000 x g EVs specifically induced proliferation of b-, but not a-cells, suggesting 
that the mechanism could be used to correct the insulin-glucagon imbalance observed in 
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gestational diabetes mellitus and type 2 diabetes mellitus. The vesicles themselves may not be 
a viable therapy. Their contents and functions are not fully known and understood, which could 
result in undesirable off-target effects. However, uncovering the mechanism underlying 
increased b-cell proliferation and function will lead to new therapeutic developments. For 
example, enhancing insulin secretion of hESC-derived b-like cells could improve transplantation 
therapies. Furthermore, understanding the pathway could identify druggable targets and lead to 
the generation of new pharmaceuticals to treat diabetes. Thus, maternal adaptation to 
pregnancy can be co-opted to treat human disease.  
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Figure 4.1 The start of pancreatic islet b-cell proliferation overlaps with the beginning of 
placental lactogen secretion in rats. 
(Left) Islet proliferation, as measured by BrdU incorporation, increases from days 10 to 17 of 
pregnancy compared to the control (Cont). Numbers in parentheses denote (n) animals. (Right) 
Compared to the control (Cont), lactogenic activity in serum increases starting at day 10 of 
pregnancy. Reprinted from Parsons et al. (1992). 
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Figure 4.2 At gestational day 13, b-cells from wildtype pregnant mice (G13) secrete higher 
levels of insulin in response to glucose stimulation than non-pregnant mice (NP). 
Adapted from Ohara-Imaizumi et al. (2013). 
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Figure 4.3 Pathway by which placental lactogen stimulates b-cell proliferation during 
mouse pregnancy. 
In mouse pregnancy, the placenta secretes placental lactogen, which binds to the prolactin 
receptor (PRLR), driving tryptophan hydroxylase (TPH) production in b-cells. TPH increases 
tryptophan (Trp) conversion to serotonin (5HT), which then binds to the receptors HTR2B and 
HTR3A. The former interaction increases proliferation and the latter drives insulin secretion. 
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Figure 4.4 Placental lactogen fails to increase human b-cell proliferation. 
Percentage of EdU-positive b-cells in human islets treated with placental lactogen. n=5. 
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Figure 4.5 Mouse pregnancy does not promote human b-cell proliferation. 
(A) Adult human islets were transplanted under the kidney capsules of mice, which were later 
impregnated. (B) Pregnancy did not impact human C-peptide concentrations, a measure of 
human insulin production, in the transplanted mice. (C) Pregnancy did not increase the 
proliferation of transplanted human b-cells as measured by EdU incorporation. (D) In contrast, 
mouse b-cells proliferated and incorporated EdU.  
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Figure 4.6 In the mouse model shown in Figure 4.5A, human CTBs or 100,000 x g EVs 
isolated from these cells stimulated adult human b-cell proliferation.  
Adult human islets were transplanted under the capsule of one kidney. To test whether the 
placenta induces b-cell adaptation to pregnancy, human CTBs were transplanted beneath the 
other kidney capsule or their EVs were injected into the tail vein. 
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Figure 4.7 CTBs and their EVs increased human b-cell proliferation in an in vivo mouse 
model. 
Mouse pregnancy specifically increased mouse b-cell proliferation as measured by EdU 
incorporation. CTBs transplanted beneath the kidney capsule promoted proliferation of human b-
cells with no effect on mouse b-cells. Tail vein injection of CTB 100,000 x g EVs similarly 
increased human b-cell proliferation. In contrast, injection of HeLa cell 100,000 x g EVs failed to 
promote b-cell replication of either species.   
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Figure 4.8 CTB 100,000 x g EVs induced b-cell proliferation in vivo. 
Unlike CTB 16,500 x g EVs, the 100,000 x g fraction increased EdU incorporation (green) in 
human b-cells, which retained expression of Nkx6.1 (blue), a marker of mature cells, and insulin 
secretion (red). 
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Figure 4.9 CTB 100,000 x g EV-stimulated b-cell proliferation was stable over several 
weeks.  
Mice transplanted with human pancreatic islets were injected with two populations of CTB EVs: 
16,500 x g and 100,000 x g. The percentage of EdU-positive human b-cells was calculated over 
time. The results showed that only the 100,000 x g EV fraction stimulated b-cell proliferation, an 
effect that was sustained over the course of these experiments.  
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Figure 4.10 HeLa cell EVs did not induce b-cell proliferation in vitro 
Human pancreatic islets were cultured with HeLa cell EVs isolated at 3 speeds: 2,000 x g, 16,500 
x g, and 100,000 x g. (Upper panel) EdU incorporation by b-cells did not increase with any HeLa 
EV treatment. (Lower panel) Ki67 staining of insulin+ cells was used as an additional marker 
proliferation. HeLa EVs had no effect. n=4 biological replicates. 
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Figure 4.11 Placental lactogen did not enhance CTB 100,000 x g EV-induced b-cell 
proliferation in vitro. 
Islets were treated with CTB EVs. EdU incorporation (upper panel) and Ki67 (lower panel) were 
used as markers of proliferating cells. Only 100,000 x g EVs increased proliferation. Addition of 
human placental lactogen had no effect. n=5 biological replicates. 
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Figure 4.12 CTB 100,000 x g EVs increased pancreatic islet insulin secretion in vitro, 
which was further enhanced by the addition of human placental lactogen. 
Islets were treated with CTB EVs and insulin response to low (2.5 mM) and high (20mM) glucose 
was measured. Only 100,000 x g EVs increased insulin secretion. Addition of human placental 
lactogen further enhanced this response.  
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Figure 4.13 Serotonin did not impact b-cell proliferation in vitro. 
Pancreatic islets were treated with CTB 100,000 x g EVs and serotonin (5HT). Addition of 5HT 
had no effect on b-cell proliferation as measured by EdU incorporation. n=5 biological replicates. 
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Figure 4.14 Sonication disrupted CTB EV-induced b-cell proliferation 
Pancreatic islets were treated with intact or sonicated CTB 100,000 x g EVs. Sonication abolished 
CTB EV-induced b-cell proliferation, which was measured by EdU incorporation. n=1. 
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Figure 4.15 CTB 100,000 x g EVs specifically stimulated b-cell proliferation to a greater 
extent than other known mitogens in vitro. 
Human pancreatic islets were cultured with CTB 100,000 x g EVs or known mitogens: harmine, 
menin inhibitor (menin inh), exendin 4, small molecule WS6, inhibitor of dual specificity tyrosine-
regulated kinase-1a (INDY), and farnesyl:protein transferase inhibitor combined with GGPTase-I 
inhibitor (FTI-GGTI). Percentage of EdU incorporation was calculated for both b-cells and a-cells. 
CTB 100,000 x g EVs specifically increased b-cell proliferation to a greater extent and with more 
specificity than known mitogens. 
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Figure 4.16 CTB 100,000 x g EVs upregulated the expression of cell cycle genes by 
pancreatic islets. 
Gene Set Enrichment Analysis (GSEA) was performed for differentially expressed RNAs. The 
results showed that CTB 100,000 x g EVs upregulated genes involved in numerous biological 
processes related to proliferation. 
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Figure 4.17 CTB 100,000 x g EVs improved generation of b-like cells from human 
embryonic stem cells (hESCs) 
(Left panel) Percentage of C-peptide-producing cells were enumerated by flow cytometry. (Right 
panel) Glucose-stimulated insulin secretion (GSIS) was calculated as the response at high 
glucose (20mM) divided by that at low glucose (2.8mM). Only CTB 100,000 x g EVs increased 
insulin production of hESC-derived b-like cells in these experiments. 
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Summary 
 In these studies, we characterized CTB EV contents and functions in promoting maternal 
adaptation to pregnancy at local and distant sites. In Chapter 2, I characterized CTB EVs by 
transmission electron microscopy and immunoblotting methods. I also profiled the global protein 
contents by mass spectrometry. In Chapter 3, I reported that these vesicles mediated 
inflammatory signals in the uterus, a local site. Specifically, CTB 100,000 x g EVs enhanced 
decidualized endometrial stromal fibroblast (dESF) transcription and secretion of 
immunomodulators with previously reported functions in endothelial cells, immune cells, and 
CTBs. Finally, in Chapter 4, we describe our discovery that that these vesicles promoted 
maternal adaptation to pregnancy in the pancreas, a distant organ. Specifically, these vesicles 
stimulated pancreatic b-cell proliferation and insulin secretion. Future studies will identify 
additional roles of these vesicles in mediating pregnancy-related changes in other maternal 
organs and tissues. The following summarizes the many directions in which this work could 
lead.  
 
Potential roles for placental extracellular vesicles at local sites 
 The EVs we studied likely have effects on neighboring CTBs. For example, the 100,000 
x g fraction is rich in fibronectin (Figure 2.8). Another group reported that migrating fibrosarcoma 
cells create an exosome trail that promotes paracrine motility via a mechanism that partially 
involves vesicular fibronectin (Sung et al., 2015; Sung and Weaver, 2017). Furthermore, CTB 
16,500 x g EVs contained Ephrin receptors, patterning molecules that influence CTB 
organization as they invade into the decidua (Red-Horse et al., 2005). Thus, CTB EVs may 
organize and promote CTB invasion from the cell column into the uterus. Understanding these 
processes in normal pregnancy will provide insights into what goes wrong in preeclampsia and 
placenta percreta, complications characterized by faulty invasion. 
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 CTB EVs likely have other roles in the decidua. For example, it has long been known 
that decidualization proceeds in advance of invading trophoblasts (Kindelberger and Nucci, 
2009). It is tempting to speculate that this observation could be explained by the cells’ release of 
EVs that signal endometrial stromal fibroblasts to decidualize.  
 CTBs could also promote spiral artery remodeling. For example, first trimester 
extravillous trophoblasts induce cell death in endothelial cells of the spiral artery in an explant 
model (Ashton et al., 2005). TNF-a in CTB 100,000 x g EVs may facilitate this endothelial cell 
death. Furthermore, I identified glia-derived nexin in CTB 100,000 x g EVs by mass 
spectrometry. This molecule promotes vascular mimicry in tumor cells (Wagenblast et al., 
2015), a process that is integral to spiral artery remodeling.  
 Placental vesicles could play a role in triggering parturition. CTB EVs contained the 
inflammatory cytokine TNF-a and induced NF-kB signaling in dESFs. Activating these pathways 
in the myometrium combined with inflammatory cytokines released by dESFs may promote 
labor. Furthermore, mass spectrometry analyses revealed that CTB EVs contained components 
of the prostaglandin pathway, additional possible mediators of parturition. EVs from term 
placentas collected following labor versus elective cesarean section will likely differ in contents 
and their ability to induce myometrial contraction, suggesting stimulation of parturition. 
Identifying mechanisms in the context of normal pregnancy will provide a foundation for 
understanding what goes wrong in pre-term labor or in cases of stalled labor. 
 CTB 100,000 x g EVs contained a number of immune molecules, including HLA-G, PD-
L1, TNF-a, CD276, CD47, and CD59. The vesicular form of these immunomodulators may be 
key to their functions in pregnancy. For example, CTB EVs were enriched for dimeric HLA-G 
(Figure 2.6). Using mass spectrometry, we detected multiple protein disulfide isomerases, which 
likely promote dimerization of this MHC class I molecule, increasing its affinity for the inhibitory 
receptors LILRB1 and LILRB2 (Bulleid and Ellgaard, 2011; Lynch et al., 2009; Shiroishi et al., 
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2006). In both vesicle types (16,500 x g and 100,000 x g), we also identified multiple 
proteasome subunits, which process antigens for peptide presentation by HLA molecules 
(Vigneron et al., 2017), suggesting that HLA-G present in CTB EVs may have antigen-
presenting capability.  
 Additional studies are needed to understand how EV proteins modulate the immune 
balance of pregnancy. For example, placental vesicles could promote recruitment of specific 
subsets of potentially beneficial immune cells to the decidua. Additionally, in vitro experiments 
could identify EV-induced changes in specific populations of peripheral or decidual cells. Models 
involving multiple immune cell types, such as antigen-presenting cells and T cells, or the 
addition of stromal cells may be required to identify other placental vesicle functions of this type.  
 
Potential roles for placental extracellular vesicles at distant sites 
 CTBs are in direct contact with maternal blood and secrete EVs into the circulation. 
Future studies will identify additional functions of these vesicles in mediating pregnancy-
associated changes throughout the mother’s body. For example, mouse pregnancy stimulates 
neurogenesis in the maternal olfactory bulb via a prolactin-mediated mechanism (Medina and 
Workman, 2018; Shingo et al., 2003). It is unclear whether a similar mechanism exists in 
humans, where adult neurogenesis is rare but occurs when neural stem cells in the 
subventricular zone give rise to neurons that migrate into the olfactory bulb (Sanai et al., 2011; 
Sorrells et al., 2018). It is tempting to speculate that the well-known sensitivity to certain 
olfactory stimuli that some pregnant women experience could be related to proliferation of 
neurons at this site. Prolactin, produced by the placenta, induces fetal neural stem cell 
proliferation in vitro (Pathipati et al., 2011). Although we failed to detect prolactin in CTB EVs, 
these vesicles could synergize with this hormone to promote adult neurogenesis during 
pregnancy.  
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 In addition to pancreatic changes, placental vesicles may influence other metabolic 
adaptations to pregnancy. Liver expansion during pregnancy is thought to be due to increased 
blood volume, as the number of hepatocytes does not increase in mice (Hollister et al., 1987). 
CTB EVs may increase hepatocyte proliferation or functions, including enzyme production and 
nutrient synthesis. 
 During pregnancy, total fat mass and adipocyte size increase (Svensson et al., 2016). 
Additionally, fat distribution shifts from subcutaneous to preperitoneal, possibly as a metabolic 
adaptation to pregnancy or to prepare for lactation (Selovic et al., 2016; Straughen et al., 2013). 
The mechanisms are unknown. Circulating EVs and hormones produced by the placenta may 
trigger these changes in body fat. 
 During late mouse pregnancy, there are drastic changes in mammary gland adipocytes 
(Cinti 2018). These cells transdifferentiate into secretory epithelial cells containing large, 
cytoplasmic lipid droplets (De Matteis et al., 2009; Morroni et al., 2004). When lactation ends, 
these cells revert to white adipocytes, returning the gland to its pre-pregnancy state (Morroni et 
al., 2004). The mechanisms underlying this phenomenon are not well understood. Exogenous 
Elf5 expression promotes adipocyte production of whey acidic protein, a component of milk, but 
is not sufficient to drive conversion into secretory epithelial cells (Prokesch et al., 2014). 
Removal of the ductal component of the mammary gland prevents adipocyte trans-
differentiation during pregnancy, indicating that a signal from ductal cells is required for this 
process (Prokesch et al., 2014). Conversion of adipocytes during mouse pregnancy and 
lactation is likely dependent on a complex network of signals from multiple cell types.  
 Additional studies are needed to determine whether a similar process occurs in humans 
and the extent of mechanistic overlap between species, especially given the rapid evolution of 
the placenta and its secreted products (Chuong et al., 2013). In terms of species-specific 
differences, the non-lactating human mammary gland contains much more stroma than its 
mouse counterpart (McNally and Stein, 2017). Stromal cell signals may be critical for human 
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mammary gland development during pregnancy. The contents of placental EVs may shift as 
pregnancy progresses to initiate mammary gland development; identifying cargo changes may 
provide mechanistic insights. Overall, future studies may implicate placental vesicles as the 
source of signals to adipocytes, ductal cells, and stromal cells in the mammary gland to initiate 
adipocyte conversion and preparation of the mother for lactation. 
 In normal pregnancy, vascular resistance decreases despite increases in total blood 
volume and cardiac output (Clark et al., 1989; Hytten, 1985). Uterine vascular resistance drops 
to a greater extent than the systemic decrease, increasing blood flow to the developing feto-
placental unit. (Bird et al., 2003). As discussed above, CTB remodeling of spiral arteries plays 
an important role in this process. In terms of other mechanisms, pregnancy is associated with 
an increase in vasodilators, such as nitric oxide and prostacyclin (Poston et al., 1995; Suzuki et 
al., 2002). Placental vesicles may play a role in systemic delivery of these molecules, as STB 
EVs contain endothelial nitric oxide synthase and nitric oxide (Motta-Mejia et al., 2017). Future 
studies may identify a function of CTB EVs in vascular relaxation, possibly due to known 
vasodilators or by acting on other pathways. 
 Placental vesicles may promote pregnancy complications, such as hyperemesis 
gravidarum, a severe and dangerous form of morning sickness. The mechanisms underlying 
nausea and vomiting during pregnancy are not understood, but gastric dysrhythmia is observed 
(Austin et al., 2019; Koch et al., 1990). Estrogen, which increases throughout gestation, inhibits 
gastric smooth muscle contractility in rats (Al-Shboul et al., 2019). Placental EVs may synergize 
with pregnancy-associated hormones to influence gut motility. Testing the effects of CTB EVs 
on digestive tract smooth muscle activity could yield clues to the mechanisms underlying 
morning sickness. 
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Stem cell systems for modelling human adaptation to pregnancy 
 The species-specificity of pancreatic adaptation to pregnancy emphasizes the rapid 
evolution of the placenta and highlights the need for human models (Chuong et al., 2013). 
Labeled placental vesicles injected into mice or other model organisms may not target the 
correct tissues or induce pregnancy-related changes due to species-specific differences. In 
Chapters 3 and 4, adult human tissues were used to study functions of CTB EVs. However, 
acquisition of healthy adult tissue is difficult, creating a very significant barrier to probing the 
effects of these vesicles across different organs. 
 Differentiated stem cell models are an alternative to difficult-to-acquire patient samples 
for testing placenta-mediated maternal physiologic changes. For example, stem cells can be 
differentiated into neurons and other brain cell types (Dutta et al., 2017). Generation of potential 
vesicle targets by differentiating human embryonic stem cells could be a powerful approach for 
studying CTB EV functions during pregnancy. 
 
Stem cell systems for increasing cytotrophoblast extracellular vesicle yield 
 The biggest barrier of the work presented here was limited numbers of primary CTBs, 
resulting in relatively low quantities of vesicles for downstream analyses and preventing 
additional purification steps. Generating CTBs from blastomere-derived stem cells or 
trophoblast progenitor cells could provide an alternative to primary cells (Genbacev et al., 2011; 
Zdravkovic et al., 2015). This system would allow for genetic manipulation to probe specific 
mechanisms underlying maternal changes induced by CTB EVs. Furthermore, increased cell 
numbers would allow for additional purification steps required for exosome isolation or for 
sufficient quantities of vesicles for RNA-sequencing.  
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Diagnostic and therapeutic potential of placental extracellular vesicles 
 A deeper understanding of CTB EV contents could result in the identification of sets of 
biomarkers associated with normal pregnancy or pregnancy complications. The probability that 
this approach will be feasible is increased by the emergence of circulating tumor exosome cargo 
as biomarkers of cancer progression (Wong and Chen, 2019). Higher concentrations of 
circulating placental vesicles are a feature of preeclampsia and gestational diabetes mellitus 
compared to normal pregnancy, indicating that the number of EVs in maternal circulation could 
serve as a biomarker of these complications (Germain et al., 2007; Knight et al., 1998; Lok et 
al., 2008; Salomon et al., 2016).  
 Although this work focused on the protein contents of CTB EVs (Chapter 2), future 
studies should also investigate the RNA cargo of placental vesicles as well as other molecules, 
such as metabolites, including lipids. Comparing the contents and functions of EVs from normal 
placentas versus those from complicated pregnancies will identify new disease markers, 
allowing for the diagnosis of pregnancy-related problems such as preeclampsia and gestational 
diabetes mellitus before symptoms appear. Because the majority of circulating vesicles are 
derived from platelets (Aatonen et al., 2017; Yuana et al., 2014), immuno-affinity isolation would 
be required to separate CTB EVs from contaminating material, enriching the placental signal. 
Future studies using antibodies against HLA-G and PLAP would determine the feasibility of this 
approach.  
 CTB EVs themselves are likely not a viable therapy. Their contents and functions are not 
entirely understood; their clinical use would likely result in off-target effects. However, 
understanding the mechanisms could enable their co-option for therapeutic use in a range of 
pregnancy complications and other diseases.  
 For example, in Chapter 4, we report that CTB 100,000 x g EVs promoted human 
pancreatic b-cell proliferation and insulin production, without increasing a-cell number. The 
mechanism could be mimicked to correct the insulin-glucagon imbalance that characterizes both 
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gestational diabetes mellitus and type 2 diabetes mellitus (Beis et al., 2005; Goke, 2008). 
Understanding the pathway could to the development of druggable targets. Alternatively, the 
mechanism could be used to improve stem cell differentiation into b-like cells before 
transplantation within an encapsulation device as a treatment for both type 1 and 2 diabetes 
mellitus (Figure 4.17) (Kirk et al., 2014; Pepper et al., 2015; Vegas et al., 2016).  
 Understanding CTB EV functions may result in treatments for pregnancy complications. 
For example, uncovering how these vesicles regulate invasion would provide insight into what 
goes wrong in preeclampsia and placenta percreta, possibly allowing for improved diagnostics, 
earlier interventions, and new treatments.  
 Mechanisms underlying placental vesicle functions could be co-opted to treat diseases 
outside of pregnancy. For example, uncovering how these EVs modulate tolerance of the semi-
allogeneic feto-placental unit may lead to new developments to prevent or treat organ transplant 
rejection or allergic diseases. Additionally, understanding the pathways involved in increasing 
body fat and changing distribution during pregnancy may result in the development of 
therapeutics for obesity. Furthermore, understanding how the placenta promotes uterine 
vascular relaxation could be co-opted to treat systemic high blood pressure.  
 Finally, understanding mechanisms underlying CTB invasion may provide insights into 
cancer. Carcinogenesis mimics processes required for normal pregnancy and vice versa. 
Tumors frequently express placenta-specific proteins, suggesting that they hijack placental 
pathways to promote disease progression (Bjerregaard et al., 2006; Devor et al., 2014). For 
example, in Chapter 2, I identified AHNAK, which promotes cancer invasion and vesicle release, 
and glia-derived nexin, which modulates vascular mimicry, in CTB EVs (Shankar et al., 2010; 
Silva et al., 2016; Wagenblast et al., 2015). Additionally, these vesicles contained lactate 
dehydrogenase, which is secreted by glioblastoma cells to stimulate myeloid cell expression of 
Natural killer group 2, member D ligands (NKG2D ligands), promoting immune evasion (Crane 
et al., 2014). Understanding how onco-fetal-placental proteins function in the original, tightly-
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regulated context of pregnancy and development may provide insight into how cancer hijacks 
these pathways and give rise to new druggable targets. Overall, future experiments identifying 
mechanisms of CTB EV-mediated adaptations to pregnancy can be exploited to treat a variety 
of diseases and improve human health. 
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